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ABSTRACT OF DISSERTATION

LOSS OF MRP1 POTENTIATES DOXORUBICIN-INDUCED
CARDIOTOXICITY IN MICE
Doxorubicin (DOX) is a broad-spectrum and effective chemotherapeutic agent,
but its use in oncologic practice is limited by dose-dependent cumulative
cardiotoxicity. DOX-induced cardiotoxicity is in large part due to its ability to
cause oxidative stress. Multidrug resistance associated protein 1 (MRP1/ABCC1)
is a member of the ATP-binding cassette (ABC) transporter superfamily. By
effluxing a wide variety of endogenous and exogenous substrates, Mrp1 plays
important physiological roles in multiple tissues and also protects normal tissues
against toxicants. However, the role of MRP1 in heart is largely unknown.
The role of Mrp1 in DOX-induced cardiotoxicity was investigated in Mrp1 null
(Mrp1-/-) and their C57BL (WT) littermates. Chronic DOX caused body weight
loss and hemotoxicity, and these adverse effects were significantly exacerbated
in Mrp1-/- vs WT mice. Importantly, loss of Mrp1 potentiated DOX-induced
cardiotoxicity, presenting as worsened cardiac function and more cellular
apoptosis in DOX treated Mrp1-/- mice. Mrp1 also protected neonatal mouse
cardiomyocytes (CM) and cardiac fibroblasts (CF) culture against DOX
cytotoxicity in vitro. This was demonstrated by the decreased cell survival, more
apoptosis and more DNA damage in DOX treated Mrp1-/- vs WT cells.
In addition, the effects of deletion of Mrp1 was studied on glutathione
(GSH)/glutathione disulfide (GSSG) homeostasis, glutathione conjugate of 4hydroxy-2-nonenal (GS-HNE) accumulation, protein oxidative damage and
expression of antioxidant enzymes. Loss of Mrp1 led to significantly higher GSH
and GSSG basal levels in heart. Following DOX treatment, Mrp1-/- CM and CF
showed increased GSH and GSSG levels vs WT cells. Meanwhile, DOX
increased expression of the GSH synthesis enzymes in Mrp1-/- but not WT cells.
Thus, increased GSH synthesis may contribute to the further increase in the
GSH pool in DOX-treated Mrp1-/- cells. DOX induced comparable increases of
GS-HNE concentration in WT and Mrp1-/- mice hearts. Finally, expression of

extracellular superoxide dismutase (ECSOD/SOD3) was significantly lower in
Mrp1-/- vs. WT CM treated with either saline or DOX.
In summary, this study is the first to document a protective role of Mrp1 in
DOX-induced cardiotoxicity. It gives critical information regarding the potential
adverse sequelae of introduction of MRP1 inhibitors as adjuncts to clinical
chemotherapy of multidrug resistant tumors.
KEYWORDS: Mrp1, doxorubicin, cardiotoxicity, glutathione, GS-HNE.
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Chapter One

Introduction

Overview

Chemotherapy usually refers to the use of chemical substances to treat cancer.
It is one of the three main methods utilized to treat cancer, and may be used in
conjunction with two other methods, radiation therapy and surgery. However,
side effects induced by chemotherapy occurring in off-target organs sometimes
significantly limit its clinic use. Acute toxicity induced by chemotherapy is usually
due to the toxic effects on rapidly dividing normal cells, like hematological toxicity
and gastrointestinal toxicity. In contrast, the late toxicity of chemotherapy is more
complex and more difficult to be treated.

Actually, in the last few decades,

because of the advances in cancer treatment, more patients are becoming longterm survivors of this disease. Therefore, it is becoming increasingly important to
understand how chemotherapy causes long-term adverse effects and how we
might prevent them.

The long-term effects of chemotherapy mainly include

cardiac toxicity, pulmonary toxicity, impairment of fertility and secondary cancers.
Among them, cardiac toxicity is one of the most severe side effects. It can occur
within days, months or even years after treatment and it leads to an important
increase of morbidity and mortality in patients receiving chemotherapy.
Doxorubicin (DOX) is a commonly used anthracycline chemotherapy agent for
a wide variety of cancers.

Large scale clinical studies show that DOX
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significantly increases the incidence of heart failure in cancer patients. Studies in
animal models and in vitro cell culture also demonstrate that DOX promotes the
generation of reactive oxygen species (ROS) and causes oxidative stress in
heart tissue or cardiomyocytes.

Understanding the defense mechanisms of

normal heart tissue against DOX toxicity will be very helpful to identify
susceptible patients in the clinic and also identify potential ways to relieve or
even prevent DOX-induced adverse effects in heart.
Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of
ATP-binding cassette (ABC) transporter superfamily. It is ubiquitously expressed
in multiple tissues and utilizes the energy of ATP hydrolysis to actively transport
a wide variety of compounds across biological membranes (cell or organelle
membranes).

It has been demonstrated to mediate a protective role in multiple

organs through the excretion of toxic compounds and their metabolites. Recently,
there is growing evidence showing that single nucleotide polymorphisms (SNPs)
of MRP1 are associated with cancer patients’ susceptibility to DOX-induced
cardiotoxicity. But the underlying mechanism is not clear. Previous work in our
laboratory found that one of these SNPs (Gly671Val) impairs by more than 85%
MRP1’s activity in effluxing glutathione conjugated 4-Hydroxy-2-nonenal (GSHNE), and HEK cells that overexpress MRP1 (Gly671Val) are more sensitive to
DOX toxicity compared to WT MRP1. Additional previous work in our laboratory
found that after a single intravenous administration of DOX, Mrp1 null (Mrp1-/-)
mice have more nuclear injury in heart compared to their wild type (WT)
littermates.

Thus, I hypothesize that MRP1 protects the heart against DOX
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toxicity by effluxing the toxic products.

This study explored the potential

protective function of Mrp1 in DOX-induced cardiotoxicity in vivo and in vitro.

Doxorubicin (DOX)
DOX and its medical use in cancer treatment
DOX, also known by its trade name Adriamycin, is an anthracycline antibiotic
chemotherapeutic drug derived from the bacterium Streptomyces peucetius var.
caesius (Arcamone et al., 1969). It is one of the most potent anti-cancer agents
and it is prescribed in isolation or in association with other drugs. DOX is used to
treat a wide variety of cancers in multiple organs, including gynecological (breast,
endometrium, ovary), urogenital (bladder, testicle), endocrine (thyroid, pancreas),
gastrointestinal (stomach), and lung cancer.

It is also effective in sarcomas

(neuroblastoma, Ewing sarcoma, and osteosarcoma), acute lymphocytic and
myeloid leukemia, and lymphomas (Minotti et al., 2004; Octavia et al., 2012). In
the clinic, DOX is administered strictly by intravenous infusion. If the medication
escapes from the vein, it can cause tissue irritation or damage. The dose and
how often the medicine is given depends on patients’ body size, blood counts,
hepatic function, and the type of cancer being treated.

DOX induces cardiotoxicity
Despite its excellent clinical efficacy as a chemotherapeutic agent, the clinical
usage of DOX has been restricted due to its potential to induce serious side
effects in cancer patients, including low white blood cell counts with increased
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risk of infection, low platelet counts with increased risk of bleeding, hair loss or
thinning, nausea, vomiting and the most severe one - cardiotoxicity (Minotti et al.,
2004; Dolye et al., 2005). Clinical studies clearly show that the incidence of heart
failure rises rapidly once the cumulative dose of DOX exceeds 550 mg/m2 in
cancer patients (Von Hoff et al., 1979; Swain et al., 2003). For example, the
incidence of heart failure is nearly 2% with a cumulative DOX dose of 300
mg/m2 but rapidly increases to 20% at cumulative doses in excess of 550 mg/m2
(Christiansen et al., 2006).

In addition, the risk of heart failure is higher in

individuals with a history of cardiomyopathy, mediastinal irradiation and heart
disease (Chatterjee et al., 2010). Since the incidence of heart failure is highly
dependent on how long these patients are being followed, it is now well-accepted
that there is no absolutely safe dose of DOX for the heart. This means that the
risk of developing heart failure in cancer patients treated with DOX remains a lifelong threat.
Clinically, DOX-induced cardiotoxicity can occur acutely (during administration
or on the day when treatment is given), subacutely (several days to months
following administration), or be delayed (years to decades following exposure).
Acute cardiotoxicity is uncommon. The incidence particularly increases when the
cumulative dose exceeds 550 mg/m 2.

It can consist of arrhythmias, a peri-

myocarditis syndrome or electrocardiographic abnormalities.

The subacute

damage develops more insidiously over months, with increasing fatigue,
tachycardia and eventually pulmonary edema and right heart congestive
symptoms. The chronic/delayed cardiotoxicity is the most clinically relevant. It
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can result in ventricular dysfunction, heart failure, and arrhythmias years or even
decades after exposure. This suggests the need for a continuous follow-up of
the cardiac status of patients who receive DOX. Chronic heart damage induced
by DOX is usually considered to be irreversible.

Thus, DOX-induced

chronic/delayed cardiac toxicity strongly impacts cancer patients’ quality of life
and even survival and thus also significantly limits the therapeutic options.

Mechanisms of DOX-induced cardiotoxicity
The cancer therapeutic effect of DOX is mainly mediated by its intercalation
into DNA or to act as a “topoisomerase poison” in dividing cells, causing DNA
fragmentation, polymerase inhibition, and decreased DNA, RNA and protein
synthesis (Rabbani et al., 2005). This mechanism is unlikely to be the major
contributor in myocardial injury, since the replication of myocytes in heart is less
active.

A number of mechanisms have been proposed to explain the

development of DOX-induced cardiotoxicity, including disruption of intracellular
iron homeostasis (Ducroq et al., 2010), free radical and reactive oxygen species
(ROS) formation (Minotti et al., 2004; Yen et al., 1996), reduction in the activity of
endogenous antioxidant enzymes (Li et al., 2000), mitochondrial damage (Green
et al., 2002), direct interaction with cell death triggers or down-regulation of cell
survival genes (Poizat et al., 2005; Liu et al., 2008; Park et al., 2011), and
activation of innate immunity (Nozaki et al., 2004; Riad et al., 2008). Although
the mechanism of DOX-induced cardiotoxicity is likely complex and multifactorial,
one of the most well-accepted hypothesis is that DOX-induced oxidative stress in
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cardiac tissue through the generation of ROS is a major contributor.
This hypothesis states that the superoxide anion (•O2-) and other reactive ROS
generated by DOX, which cycles between the quinone and semiquinone,
contribute significantly to cardiac pathology (Gewirtz, 1999; Minotti et al., 2004).
First, a DOX molecule accepts one electron from NADH or NADPH to form the
reduced semiquinone radical of DOX. In heart, enzymes that can catalyze this
reaction

include

mitochondrial

NADH

dehydrogenases

present

in

the

sarcoplasmic reticulum and mitochondria as well as cytosolic enzymes such as
NADPH

dehydrogenase,

xanthine

oxidase

and

nitric

oxide

synthases

(Pawłowska et al., 2003; Nohl et al., 1998; Vásquez-Vivar et al., 1997; Fogli et al.,
2004). Then, the unpaired electron is donated to molecular oxygen by DOXsemiquinone, forming •O2- (Figure 1.1).

Once the •O2- is produced, the

dismutation of •O2- to hydrogen peroxide (H2O2) is catalyzed by superoxide
dismutase (SOD) or may occur spontaneously. H2O2 is a relatively stable and
low-toxicity molecule, and can be eliminated by catalase, glutathione peroxidase
(Gpx) and thioredoxin peroxidase (Tpx) under physiological conditions. However,
in the presence of transition metal ions, especially iron ions, the overproduction
of H2O2 and •O2- can be converted through Fenton and Haber-Weiss reaction to
a large amount of hydroxyl radical (•OH), which has a very short half-life and is
extremely reactive and toxic. It reacts with almost any oxidizable compound in its
vicinity and thus induces damage to all types of macromolecules, including lipids,
nucleic acids, and proteins.

Among these macromolecular damages, lipid

peroxidation is probably the most important. The lipid peroxidation can result in
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severe membrane dysfunction and significant damage to mitochondrial structural
integrity and function.

Therefore, it is the ROS released by this DOX redox

cycling, rather than DOX itself that is most likely responsible for drug induced
adverse cardiotoxicity.
A body of evidence in animal models supports the hypothesis that ROS
contributes to DOX-induced cardiotoxicity.

For example:

chronic DOX

cardiotoxicity has been associated with a marked drop in expression of the
antioxidant enzyme manganese superoxide dismutase (MnSOD) (Li et al., 2000;
Stěrba et al., 2011), while overexpression of MnSOD protects mitochondrial
complex I against DOX-induced cardiotoxicity in MnSOD transgenic mice (Yen et
al., 1996; Yen et al., 1999). The overexpression of glutathione peroxidase (Gpx)
protects the isolated mouse heart from toxicity induced by DOX perfusion, as well
as heart damage in mice treated with single high dose of DOX (15 mg/kg) (Xiong
et al., 2006).

Furthermore, multiple antioxidant molecules show promising

protective effects in myocyte cell culture study or small animal studies (Oliveira et
al., 2004; Lou et al., 2005; Singal et al., 2000).
This importance of antioxidant enzymes and molecules in protecting against
DOX-induced cardiotoxicity also provides some explanation of why the heart is
particularly susceptible to DOX. First, the heart has a large density/volume of
mitochondria because it requires large amounts of energy.

However,

mitochondria are both important sources of ROS formation and susceptible
targets of ROS damage. The abundance of mitochondria existing in heart could
cause extensive production of ROS and exacerbate the ROS-induced tissue
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damage, which is related to mitochondrial dysfunction (Hansen at al., 2006).
Second, the heart has relatively lower amounts of antioxidant enzymes like SOD
and catalase compared to other tissues, such as the liver (Gao et al., 2008). In
fact, after exposure to DOX, cardiomyocytes show a further decrease in the
content/activity of antioxidant enzymes, including GPx, cytosolic Cu,ZnSOD and
mitochondrial MnSOD, at least at some specific time points (Li et a., 2000).

Current treatment for DOX induced cardiotoxicity
At present, there are three major approaches for primary prevention of DOXinduced cardiotoxicity.

One strategy is to reduce cardiotoxic potency by

administering DOX via continuous infusion instead of one bolus injection. The
idea behind this approach is that the DOX concentration in the heart is lower
when a continuous infusion is given, leading to lower clinical cardiotoxicity, while
DOX concentrations in tumor tissue are the same with continuous or bolus
administration (Pacciarini et al., 1978). Thus, increasing infusion duration clearly
reduced cardiotoxicity without compromising oncological efficacy.

Another

strategy is to use liposomal encapsulation, or using a less cardiotoxic derivative
(e.g., epirubicin or idarubicin).

Liposomal DOX is trapped within the internal

aqueous compartment by the ion gradient difference and helps to restrict DOX
inside the vessel wall of organs with tight capillary junctions (normal tissues such
as the heart), but allows DOX to more readily penetrate through tumor
vasculature, which is more fragile and permeable than healthy tissue. Thus,
liposomal DOX can significantly decrease the DOX concentration in the heart
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without impairment of its anti-cancer efficacy (Rahman et al., 2007; Safra et al.,
2000). However, because of its high cost, liposomal DOX is not widely used yet.
In addition to changing the way of administration and drug formulation, another
approach to relieve DOX-induced cardiotoxicity is to use a cardioprotective agent
in conjunction with DOX treatment. Dexrazoxane is the only cardioprotective
drug currently available in the clinic. Dexrazoxane’s ability to chelate iron was
previously thought to be the primary mechanism of cardioprotection. However,
the lack of similar effects when other even stronger iron chelators are used has
questioned this mechanism (Simůnek et al., 2009). Finally, because there is
some concern that dexrazoxane may attenuate the chemotherapeutic efficacy of
DOX, it is recommended that its use be initiated only after a patient has received
more than 300 mg/m2 of DOX.
At present, scientists continue to identify additional optimal ways to address
this problem, and some potential candidates are under investigation. One major
category is antioxidant chemicals and free radical scavengers. For example,
Carvedilol, a clinically approved adrenergic blocking agent with potent antioxidant activity, has been found to be protective against DOX-induced ROS
generation and apoptosis in rat heart in vivo (Oliveira et al., 2004). Another
antioxidant, probucol, has been shown to prevent the left ventriculal ejection
fraction (LVEF) decrease in DOX-treated rats (Li et al., 2000; Lou et al., 2005;
Singal et al., 2000).

However, while the animal model studies and in vitro

experiments have generally shown the favorable effects of antioxidant therapy,
the results of clinical studies of antioxidants in patients have been inconsistent
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due to differences in the antioxidant agent used, timing of therapy, type of
malignancy and chemotherapeutic regimen. Continuous efforts in elucidating the
pathogenic mechanisms, as well as identifying new therapeutic targets, will
certainly be necessary for the development of more effective therapies.

ATP-binding cassette (ABC) transporter superfamily
The ATP-binding cassette (ABC) transporter superfamily is one of the largest
and most broadly expressed transmembrane protein superfamilies known. The
members are classified as ABC transporters based on the sequence and
organization of their ATP-binding domain, also known as NBDs (nucleotide
binding domains). ABC transporters are ubiquitous integral membrane proteins
and the vast majority of them utilize the energy of ATP hydrolysis to actively
transport a wide variety of substrates across extra- and intracellular membranes.
Their substrates include phospholipids, ions, peptides, steroids, polysaccharides,
amino acids, organic anions, bile acids, drugs, and other xenobiotics (Linton et
al., 2007; Higgins et al., 2001). These transport activities are critical for most
aspects of cell physiology and broadly impact human health and disease.
Genetic variation in these genes is the cause or contributor to a wide variety of
human disorders, including cystic fibrosis, neurological disease, retinal
degeneration, cholesterol and bile transport defects, anemia, and drug response
phenotypes (Mendoza et al., 2007; Leonard et al., 2003; Kim et al., 2009;
Lambrechts et al., 2015).
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ABC transporter subfamilies and structure
Phylogenetic analysis places the 48 known human ABC transporters into
seven distinct subfamilies (ABCA through ABCG) (Table 1.1).

All ABC

transporters share a common architecture comprising two hydrophilic nucleotidebinding domains (NBDs) and two hydrophobic transmembrane domains (TMDs) /
membrane spanning domains (MSDs) (Linton et al., 2007).
NBDs are located in the cytoplasm and each NBD contains three conserved
domains: Walker A and Walker B motifs, found in all ATP-binding proteins, and a
signature (C) motif, located just upstream of the Walker B site. The C motif is
specific to ABC transporters and distinguishes them from other ATP-binding
proteins.

NBDs are the sites which bind and hydrolyze ATP and also are

involved in coupling the energy released by binding and hydrolysis of ATP to
processes of cross membrane transport. TMDs are usually composed of at least
six transmembrane (TM) α-helices. They form the pathway through which solute
crosses the membrane and also determine the specificity of the transporter
through substrate-binding sites (Higgins et al., 2001; Linton et al., 2007).
Based on the position and orientation of membrane spanning segments and
other domains (predicted by computer modeling and laborious biochemical
experiments), there are three most plausible membrane topology models for the
key ABC transporters.

As shown in Figure 1.2, ABCB1 (MDR1/Pgp) is a "full

transporter" with six TM helices in both TMDs, each followed by an NBD. A
similar membrane topology has been predicted for ABCB4 (MDR3), ABCC4
(MRP4), ABCC5 (MRP5), and ABCB11 (BSEP) as well. In addition to an MDR1-
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like core, MRP1 contains an additional N-terminal segment of about 280 amino
acids.

A major part of this region is membrane-embedded with five

transmembrane helices (TMD0), while a small cytoplasmic loop of about 80
amino acids (CL) connects this area to the core region. Transporters with similar
structure include ABCC2 (MRP2), ABCC3 (MRP3), and ABCC6 (MRP6). The
last category includes half-size transporters which have only one TMD fused to
one NBD, for example, ABCG2 (BCRP) subfamily. These transporters dimerize
to form a biologically active ABC-transporter.

Mechanisms of the transport process
ABC transporters are mostly unidirectional. In bacteria, ABC transporters are
predominantly involved in the import of essential compounds (sugars, vitamins,
metal ions, etc.) into the cell, while in eukaryotes, most ABC transporters move
compounds from the cytoplasm to the outside of the cell or into an intracellular
compartment, such as endoplasmic reticulum, mitochondria, peroxisome (Saurin
et al., 1999). Despite the diversity of localization and substrate specificity, ABC
transporters share a common basic mechanism of transport: two NBDs bind and
hydrolyze ATP, and energize unidirectional substrate transport, which occurs
through a translocation pathway provided by two MSDs.
For ABC transporters that efflux the substrate from mammalian cells, an ATPswitch model (Higgins et al., 2004; Dong et al., 2005) is popularly used to explain
this transport process in four steps (Figure 1.3). (a) The transport cycle is
initiated by the interaction of substrate with the TMDs from the intracellular face
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of the membrane. (b) The substrate binding induces a conformational change in
the TMDs, and this conformational change is transmitted to the NBDs to initiate
binding of two molecules of ATP. Basically, two NBDs interact with each other to
form two composite nucleotide binding sites. At each nucleotide binding site, one
ATP molecule is sandwiched between the Walker A and Walker B motifs from
one NBD and the LSGGQ ABC signature motif (C-motif) from the other NBD. (c)
ATP binding induces further conformational changes in the NBDs, which are
transduced to the TMDs: a high-affinity substrate binding site at the inside of the
membrane is reoriented to be exposed to the outside of the membrane.
Simultaneously its affinity to substrate is reduced, resulting in extracellular
release of the substrate. (d) Finally, ATP hydrolysis causes the transporter to be
reset and the binding site reoriented back to face the inside of the membrane and
affinity restored. It is clear that both NBDs are required, and both must hydrolyze
ATP, and they do so by an ‘alternating catalytic cycle’ mechanism in which only
one NBD hydrolyses one ATP at a time.

ABC transporters in cancer and normal tissues
Overexpression of certain ABC transporters has been associated with
chemotherapy resistance in many cancer types, like leukemia, breast cancer,
lung cancer and ovarian cancer.

The mechanisms involved are revealed by

biochemistry studies that demonstrate that some ABC transporters efflux
cytotoxic drugs out of the cell, thus keeping intracellular drug concentrations
below the cell-killing threshold. These ABC transporters are called multidrug
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resistant (MDR) proteins. They include, but are not limited to, transporters such
as P-glycoprotein (Pgp), MPR1, MRP2, and BCRP.
Although initially being found in drug resistance tumor cells, some ABC
transporters are ubiquitously expressed in many normal tissues, including bloodbrain barrier, liver, kidney, placenta, etc. Recently, there is a growing body of
evidence showing the importance of ABC transporters in multiple normal organs’
defense, such as regulating central nervous system permeability, protecting
testicular tissue and the developing fetus. They are also involved in the toxin
excretion from the liver, gastrointestinal tract and kidney, to protect the entire
organism. These protective roles are conducted mainly through the excretion of
toxic compounds and their metabolites (Leslie et al., 2005; Fromm, 2004; Sarkadi
et al., 2004).

Multidrug resistance-associated protein 1 (MRP1/ABCC1)
Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the
ABCC subfamily. The murine (Mrp1) and human (MRP1) orthologues of MRP1
are 88% identical. MRP1 was first discovered in a drug-selected human small
cell lung carcinoma cell line, H69AR, which had developed drug resistance to
DOX without the increase in expression of Pgp (Cole et al., 1992). MRP1 is a
190 kDa heavily glycosylated ABC transporter that contains three TMDs and two
NBDs. The additional transmembrane domain TMD0, and the intra-cellular loop
between TMD0 and TMD1, are important for trafficking and insertion of MRP1 in
the plasma membrane (Westlake et al., 2005). With extensive investigation in
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past two decades, MRP1 has been demonstrated to play an important role in the
development of drug resistance of various types of cancer (Hsia et al., 2002;
Triller et al., 2006; Nooter et al., 1997a; Nooter et al., 1997b; Sullivan et al.,
1998).

It does not appear to play a significant role in the absorption or

eliminations of drugs, but does seem to be an important modulator of drug tissue
exposure and metabolite cellular elimination.

MRP1 tissue distribution and intracellular localization
Beyond the tumor tissues, constitutive MRP1 is ubiquitously expressed in most
normal tissues, especially in heart, skin, lung, brain capillary endothelial cells,
and small intestine (Flens et al., 1996; Nies et al., 2004). In polarized epithelial
cells, MRP1 is usually found in the basolateral membrane. While being primarily
located in the plasma membrane, MRP1 is also found in the membrane of
intracellular organelles such as endocytic vesicles, lysosomes located near the
nucleus, trans-Golgi vesicles, and the mitochondria (Rajagopal et al., 2003;
Gennuso et al., 2004; Jungsuwadee et al., 2009).

Substrates of MRP1
MRP1 effluxes a wide range of endobiotics and xenobiotics (Figure 1.4).
These substrates are usually amphiphilic anionic compounds, including
glutathione (GSH) and glutathione disulfide (GSSG) as well as GSH, glucuronide
and sulfate conjugated organic anions, such as leukotriene C4 (LTC4) and GSHNE (Leier et al., 1994; Cole and Deeley. 1998; Renes et al., 2000; Leslie et al.,
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2001; Jungsuwadee et al., 2012).

MRP1 also transports nonconjugated

hydrophobic compounds in the presence of GSH, such as the natural product
type chemotherapeutic agents Vinca Alkaloids and mutagens, such as aflatoxin
B1 (Cole and Deeley., 2006).

MRP1 protects normal tissues against toxic effects of xenobiotics
In normal polarized epithelial cells, MRP1 is usually found on the basolateral
membrane, and thus may serve to efflux substrates into the bloodstream or
interstitial space. Generation and characterization of Mrp1-/- mice demonstrated
that this protein is not essential for normal viability and fertility of mice (Wijnholds
et al., 1997; Lorico et al., 1997). However, these Mrp1-/- mice show impaired
ability to transport some endobiotics and xenobiotics. For example, Mrp1-/- mice
are hypersensitive to the anticancer drug etoposide, and exhibit reduced
inflammatory responses attributed to disrupted leukotriene homeostasis caused
by the inability of these mice to efflux LTC4 (Wijnholds J et al., 1997). Detailed
analysis of the etoposide toxicity indicates that Mrp1 contributes to the protection
of the oropharyngeal mucosal layer and the seminiferous tubules of the testis,
and it appears very likely that normally Mrp1 restricts access of etoposide to
these tissues (Wijnholds et al., 1998). Mrp1-/- mice also show impairment in the
efflux of [14C] grepafloxacin and Fluo 3 in the skin (Li et al., 2005). In addition, a
role for Mrp1 was demonstrated in cerebral amyloid-β (Aβ) clearance and brain
accumulation, being identified as a potential target for treatment or preventing
Alzheimer’s disease and cerebral amyloid angiopathy (Krohn et al., 2011). Mrp1-
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/- mice are also hypersensitive to sodium arsenite, sodium arsenate, and
antimony potassium tartrate (Rappa et al., 1997). These data demonstrate that
Mrp1 protects the normal tissues by effluxing endobiotics and xenobiotics and
thus prevents the toxicants’ accumulation in cell or tissue. However, it is largely
unknown how Mrp1 functions in heart, especially when the heart is under stress,
such as that induced by DOX treatment.

Clinical association between genetic variants of MRP1 and anthracycline
induced cardiotoxicity
Genetic variations at the level of single nucleotide polymorphisms (SNPs) are
well demonstrated to be associated with the differences of disease susceptibility
and therapy response among the population.

More recently, inter-individual

difference in genes encoding the drug transporters have received considerable
attention because of their ability to contribute to differences in drug absorption,
distribution, and elimination that ultimately affect both drug efficacy and toxicity
(Cole, 2014a).

Accumulating case-control clinical studies have shown that

several MRP1 SNPs are associated with the susceptibility to cardiotoxicity
observed in cancer patients treated with anthracycline (Table 1.2) (Wojnowski et
al., 2005; Semsei et al., 2012; Visscher et al., 2012). Although the biological
function of these SNPs are not fully understood, we expect these SNPs could
potentially change the expression and function of MRP1 and further impair the
efflux of substrates, and finally contribute to the susceptibility to DOX-induced
cardiotoxicity.

Prior studies by our laboratory focused on one of these SNPs
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(Gly671Val).

Our laboratory demonstrated that HEK cells that overexpress

MRP1 (Gly671Val) are more sensitive to DOX toxicity compared to cells that
overexpress WT MRP1. Although human MRP1 can efflux DOX, this mutant
MRP1 does not significantly increase the intracellular concentration of DOX in
HEK cells, but impaired by more than 85% MRP1’s activity in effluxing GS-HNE,
which is an important toxic metabolite of lipid peroxidation (Jungsuwadee et al.,
2012). This implies that MRP1 could play an important role in heart defense
against DOX toxicity by effluxing toxic substrates other than DOX. Here, we will
focus on MRP1’s substrates that are related to oxidative stress.

Oxidative stress
Oxidative stress refers to a harmful condition that occurs when there is an
excess of ROS, a failure of antioxidant defense systems, or both (Sies, 1997;
Dasuri et al., 2012). ROS include free radicals, such as •O2- and •OH, and
nonradicals capable of generating free radicals, such as H2O2. These ROS can
be derived from several intracellular sources, including mitochondria, NAD(P)H
oxidase, xanthine oxidase, and uncoupled nitric oxide synthase, as well as from
exogenous factors such as DOX exposure. To protect cells from the damage
caused by ROS, organisms have evolved a variety of antioxidant systems to
rapidly and efficiently remove ROS or inhibit their activities and maintain
appropriate redox homeostasis (Figure 1.5).

The main antioxidant enzymes

include superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx),
peroxiredoxin (Prx) and glutathione S-transferase (GST).
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SOD converts two

•O2- into one molecule of H2O2 and one molecule of O2, while catalase further
catalyzes the decomposition of H2O2 into H2O and O2. The main reactions that
GPx and Prx catalyze are to reduce H2O2 to H2O by consumption of reduced
GSH or reduced thioredoxin (Trx). In addition to these antioxidant enzymes,
there are also small antioxidant molecules such as GSH, peroxiredoxin (Prx),
thioredoxin (Trx), vitamin C, and vitamin E. Oxidative stress has been implicated
in numerous diseases at multiple organs, while heart is particularly vulnerable to
oxidative stress induced damage due to relatively low expression/activity of
antioxidant enzymes, and the low regeneration ability of the highly differentiated
cardiomyocytes.

Here, this dissertation mainly focuses on GSH/GSSG

homeostasis and the lipid peroxidation product 4-Hydroyx-2-nonenal (HNE),
because GSH, GSSG and GS-HNE are all substrates of MRP1.

GSH and GSSG homeostasis in cells
GSH is a tripeptide - γ-glutamyl-cysteinyl-glycine with a gamma peptide
linkage between the carboxyl group of the glutamate side chain and the amine
group of cysteine, which is attached by normal peptide linkage to a glycine.
Reduced GSH is the most abundant intracellular non-protein thiol in almost all
aerobic species. Due to its cysteinyl moiety, GSH is a nucleophile that provides
electrons to electrophilic species to form GSSG.

GSSG can be catalytically

reduced back to GSH by the NAD(P)H dependent GSH reductase (GR) (Figure
1.6). The continued function of the redox cycle activity is dependent on the
availability of NADPH, of which the pentose phosphate pathway is a major
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source (Lushchak, 2012). Under physiological conditions, reduced GSH is the
major form, with its concentration from 10 – 100 fold higher than the oxidized
form, present as mixed disulfide (mainly GS-S-protein) and the disulfide (GSSG).
However, this ratio will decrease in the presence of ROS, due to the rapid
oxidation from GSH to GSSG. Therefore, the GSH/GSSG ratio is an important
indicator of the redox environment. Maintenance of GSH homeostasis plays a
vital role in a multitude of cellular processes, including drug and free radical
detoxification, cell differentiation, proliferation and apoptosis (Jones, 2008).
In addition to its role in elimination of ROS, GSH is also a signaling molecule.
It is added to proteins as a post-translational modification (Pompella et al., 2003)
to form S-glutathionylated proteins. It interacts with nitric oxide (NO) to modify its
bioavailability (Hogg et al., 2002). It also modifies the activity of neurotransmitter
receptors and may itself be active as a neurotransmitter (Oja et al., 2000). In
conclusion, GSH is a multifunctional molecule with diverse and still emerging
functions.

GSH synthesis and metabolism
GSH is synthesized in all mammalian cells, and the liver is a major site. The
synthesis from the precursor amino acids cysteine, glutamate and glycine is
accomplished by a consecutive action of two ATP-dependent enzymes (Figure
1.7). First, gamma-glutamate-cysteine ligase (GCL), a heterodimer of a catalytic
subunit (GCLc) and a modulatory subunit (GCLm), forms an unusual peptide
bond between the γ-carboxyl of glutamate and the amino group of cysteine using
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the energy provided by the hydrolysis of ATP (Lu, 2013). This is the rate-limiting
step of GSH synthesis in vivo.

The second step is addition of glycine to γ-

glutamylcysteine. This reaction is catalyzed by glutathione synthase (GSS) and
driven by the hydrolysis of another ATP. After its synthesis, GSH is delivered to
some intracellular compartments, including mitochondria, endoplasmic reticulum,
nucleus, and to the extracellular space (e.g., blood plasma and bile) for utilization
by other cells and tissues (Forman et al., 2004).
The overall rate of GSH synthesis is controlled by several factors, including: (i)
availability of the substrate, mainly L-cysteine. This is determined by membrane
transport activities of the three sulfur amino acids cysteine, cystine and
methionine, and the conversion of methionine to cysteine via the trans-sulfuration
pathway (Grimble et al., 1992); (ii) the activity of the rate-limiting enzyme - GCL.
This is determined by the expression level and relative ratio between its two
subunits GCLc and GCLm (Chen et al., 2005). In most tissues, GCLc is found in
excess compared to GCLm, while the binding of GCLc to GCLm dramatically
decreases the sensitivity of the holoenzyme to GSH inhibition, presumably by
changing the conformation of the enzyme; (iii) extent of feedback inhibition of
GCL, especially GCLc by GSH (Taylor et al., 1996). Additionally, in some cases,
the provision of ATP for GSH synthesis could represent another limiting factor. It
is worth noting that both GCL and GS are sensitive to oxidative stress, and their
expression is mainly under the regulation of the Nuclear factor (erythroid-derived
2)-like 2 (Nrf2), a transcription factor that regulates a wide array of antioxidant
responsive element-driven genes in various cell types (Lu, 2009).
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Although GSH is synthesized intracellularly in all the cell types, its
biodegradation occurs outside of cells (Figure 1.8). Since GSH is not susceptible
to proteolysis due to its unusual γ–carboxyl peptide linkage, GSH is resistant to
intracellular degradation and its degradation only occurs in cell types that have
gamma-glutamyl transpeptidase (γGT), an ectoenzyme on the cell membrane.
γGT removes the γ–glutamyl moiety from GSH under physiological conditions,
and then dipeptidase removes the glycyl moiety (Ballatori et al., 2009). The
breakdown products (glutamate, glycine, and cysteine) can be taken up into the
cell for GSH synthesis. In yeast, an alternative pathway of GSH degradation is
mediated by a novel cytosolic protein complex involving three new genes Dug1,
Dug2 and Dug3 (Ganguli et al., 2007; Baudouin-Cornu et al., 2012).

MRP1 and GSH/GSSG homeostasis
The relationship between GSH and MRP1 is complex. On one hand, GSH
influences MRP1’s ATP-dependent transport activity by either its direct
conjugation to the substrates or binding MRP1 and stimulating its transport
activity. On the other hand, MRP1 is able to efflux GSH directly (Cole, 2014b).
GSH itself is a low affinity substrate of MRP1 (Km = 1-5 mM), but it is a suitable
substrate for MRP1 under physiological conditions, considering that the
physiological concentration of GSH is in the mM range in most cells.

Co-

transport of GSH with another substrate is another mechanism of GSH transport
through MRP1. For example, depleting GSH with BSO inhibits transport of
daunorubicin, vincristine, and aflatoxin B1 (Versantvoort et al., 1995; Rappa et al.,
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1997; Salerno and Garnier-Suillerot, 2001). In addition, the ability of MRP1 to
transport GSH can be markedly enhanced in vitro by a variety of xenobiotics (e.g.,
verapamil,

vincristine,

the

antivirals

indinavir

and

nelfinavir),

including

bioflavonoids (e.g., apigenin) (Loe et al., 2000; Cole., 2014b).
Whereas the role of GSH in preventing oxidative stress is well understood, the
precise dynamics of MRP1 in regulating cellular GSH levels require clarification.
It has been observed that the GSH content in cells overexpressing MRP1 is
much lower than that of control cells, while Mrp1-/- mice have increased basal
levels of GSH in multiple tissues (Rappa et al., 1997; Wijnholds et al., 1997).
Minich et al (2006) also reported that astrocytes isolated from Mrp1-/- mice have
50% more intracellular GSH. Further, inhibiting MRP1 or selectively knocking
down MRP1 causes a decrease in GSH release in both unstressed and stressed
conditions (Minich et al., 2006; Sreekumar et al., 2012). This means that the
basal intracellular level of GSH is affected by its efflux through MRP1. This is
further demonstrated by the observation that the basal level of GSH export in
Mrp1-/- mice stem cells is approximately one half of that observed in wild type
cells (Cole et al., 1990; Rappa et al., 1997). The MRP1-mediated GSH transport
in different cell types in specific tissue/organ has also received considerable
attention. For example, in the brain, astrocytes maintain the redox balance of the
cellular milieu by the MRP1-mediated extrusion of GSH (Minich et al., 2006).
In addition to GSH, GSSG has also been shown to be effluxed across the
plasma membrane through MRP transporters (Hirrlinger et al., 2001; 2005;
Minich et al., 2006; Cole and Deeley, 2006). As discussed above, GSSG tends
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to accumulate in cells under conditions of oxidative stress.

Because of its

deleterious pro-oxidant activities, maintenance of low levels of GSSG (and an
appropriately low GSSG/GSH ratio) is important for normal cellular function. This
maintenance is accomplished mostly by a combination of the reduction of GSSG
back to GSH by GR and the efflux of GSSG by MRP1 (and MRP2). MRP1’s
affinity for GSSG (Km ∼100 μM) is significantly higher than that for GSH (Km ∼ 15 mM) (Cole SP et al, 2006).

MRP1-mediated GSSG efflux occurs during

oxidative stress in several cell types, including astrocytes and endothelial cells
(Minich et al., 2006; Ellison and Richie et al., 2012). A recent study implicates
MRP1 as a neuroprotective factor against stroke and attributes this ability to
MRP1-mediated efflux of GSSG, a known trigger of neuronal cell death (Park et
al., 2011). These data indicate the role of MRP1 in the cellular response to
oxidative stress. Thus, loss of MRP1 influences the intracellular level of GSH
and GSSG, may disrupt the balance of the GSH/GSSG redox couple, and finally
impair normal tissues’ ability to defend against oxidative stress-induced injury.

Lipid peroxidation
The free radical-mediated peroxidation of lipids has received a great deal of
attention in connection with oxidative stress in vivo.

Free radicals, for example

hydroxyl radical (OH·) generated from H2O2 via the Fenton– and Haber–Weiss
reactions, mediate the removal of a hydrogen atom (H•) from a lipid (LH), which
yields a lipid radical (L•). In the propagation phase, L• reacts with O2 and forms
a lipoperoxyl radical (LOO•), which in turn reacts with another polyunsaturated

24

fatty acids (PUFA) to yield a new L• and a lipid hydroperoxide (LOOH) (Figure
1.9A). Thus, one free radical can generate a high number of lipid hydroperoxides
until the chain reaction is terminated by a chain-breaking antioxidant.

Lipid

peroxidation has been implicated in various diseases and aging, including
inflammation, atherosclerosis, cataract formation, chronic degenerative diseases
of the nervous system, and chronic liver disease (Sultana et al., 2013; Yadav et
al., 2013; Parola et al., 1996).

HNE formation
Since lipid hydroperoxides (LOOH) produced by the chain reaction of lipid
peroxidation are unstable, they decompose to various secondary products of lipid
peroxidation, including malondialdehyde (MDA) and HNE (Figure 1.9B). The
physiological concentration of HNE is in the submicromolar range (<0.1 μM),
while in oxidative stress, even micromolar levels can be observed (Esterbauer et
al., 1991; Butterfield and Stadtman, 1997). Thus, HNE can be regarded as a
biomarker of oxidative stress.
HNE is very hydrophobic, so that it is mostly associated with the membranes
where it is produced from the peroxidation of arachidonic and linoleic acids.
Since HNE is relatively stable, it can diffuse remarkable distances from the site of
formation to different cellular compartments. It has three main functional groups:
an aldehyde, a double bond (alkene) between carbon C2 and C3, and a
secondary alcohol at carbon C4 (Figure 1.10).
molecule

that easily reacts

with

HNE is a highly electrophilic

glutathione,
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proteins

and, at

higher

concentrations, with DNA.

HNE reacts with cysteine, histidine, and lysine

residues of proteins, likely resulting in functional impairment (Esterbauer et al.
1991) (Figure 1.11).
To protect macromolecules from modification or adduction by HNE,
mammalian cells metabolize 4-HNE rapidly (Figure 1.12).

One important

pathway of detoxification is through conjugation with GSH, either spontaneously
or through GSH-S-transferases (GST) to form GS-HNE, which must be effluxed
to alleviate intracellular toxicity (Volkel et al., 2005). In addition, HNE metabolism
includes reduction to the corresponding alcohol, 1,4-dihydroxy-2-nonene (DHN)
or oxidation to the corresponding acid, 4-hydroxy-2-nonenoic acid (HNA) (Alary
et al., 2003; Volkel et al, 2005). GS-HNE can also be metabolized via an NADHdependent alcohol dehydrogenase (ADH)-catalyzed reduction to GS-DHN and/or
aldehyde dehydrogenase-catalyzed oxidation to GS-HNA.

The biological

activities of these GSH conjugates are not yet well characterized.

MRP1 and HNE detoxification
As discussed above, the GSH/GST system is a well-known mechanism in the
cellular defense against oxidative stress. The excretion of GSH conjugates is
important

in

decreasing

intracellular

concentrations

of

toxins

because

conjugation reactions can be reversible. In addition, some metabolites become
more toxic on conjugation with GSH.
The conjugation of HNE with GSH forms a less toxic metabolite, GS-HNE, but
its accumulation inside the cell can still generate toxicity due to end-product
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inhibition of relevant GST, with subsequent accumulation of HNE and ensuing
toxicity (Diah et al., 1999; Renes et al., 2000). Thus, the extrusion of GS-HNE is
required for preventing these adverse toxicities. Evidence for a significant role of
MRP1 as a transmembrane efflux transporter for GS-HNE conjugates has been
reported, and the Km is in the µM range. In a human small cell lung cancer cell
line, the expression of MRP1 was associated with protection against HNE toxicity
(Renes et al., 2000). Our laboratory reported that mutant MRP1 (Gly671Val)
impaired MRP1’s ability to efflux GS-HNE by more than 80%, and caused a
higher sensitivity to DOX toxicity in HEK cells (Jungsuwadee et al., 2012). That
study also found that HNE-adducted protein is increased in mouse heart after
DOX treatment and that sarcolemmal membrane vesicles from Mrp1-/- mice are
unable to transport GS-HNE, indicating that Mrp1 is the only ATP-dependent
efflux transporter in the mouse heart (Jungsuwadee et al., 2006).

Thus,

understanding of MRP1’s effects on GS-HNE efflux and intracellular GS-HNE
accumulation are needed to clarify the potential role of MRP1 in normal heart
tissue defense against oxidative stress.

Research Objectives
This study explored the potential protective function of Mrp1 in DOX-induced
cardiotoxicity. Mrp1-/- mice and their WT littermates were used as a study model.
Although Mrp1 is highly conserved between human and rodents with 88%
sequence homology, the human isoform (MRP1) is able to transport DOX,
whereas murine Mrp1 has only a negligible ability to transport this anthracycline
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(Stride et al., 1997). Therefore, the Mrp1-/- mouse provides a good model to
study the role of Mrp1 in DOX cardiotoxicity separately from the effects of DOX
retention. Of course, the diiference of human MRP1 and murine Mrp1 regarding
the efflux of DOX could limite the translation from experimental finding in mouse
model to clinical research.
In this study, after giving the mice chronic DOX treatment, the left ventricle
function, heart apoptosis and heart fibrosis were evaluated. Effects of Mrp1 on
DOX cytotoxicity were also investigated in two major cell components of heart:
neonatal mouse cardiomyocytes and neonatal cardiac fibroblasts, including the
effects on cell survival, cell apoptosis, and DNA damage. The mechanisms of
Mrp1-mediated protection were further investigated based on known functions of
Mrp1, mainly focusing on glutathione homeostasis, GS-HNE accumulation, and
protein oxidative damage.
The results of the current study demonstrate that Mrp1 protects mouse heart
against DOX-induced cardiotoxicity.

Clinical studies show an association

between multiple genetic variants of MRP1 gene and cancer patients’
susceptibility to DOX induced cardiotoxicity.

Thus, our study may provide

explanations for these clinical observations if any SNPs impair MRP1’s
expression or activity. It will further help to identify these susceptible patients
and modify chemotherapy strategies for them, and thus prevent such druginduced toxicity.
This dissertation research was conducted to test the following hypotheses:
1. Loss of Mrp1 will potentiate chronic DOX-induced cardiac dysfunction in mice;
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2. Loss of Mrp1 will sensitize cardiomyocytes and/or cardiac fibroblasts to DOX
cytotoxicity;
3. GSH/GSSG homeostasis will be disrupted in Mrp1-/- mouse heart.
4. Loss of Mrp1 will cause GS-HNE accumulation in mouse heart tissue after
DOX administration.
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Figure 1.1. Schematic illustration of redox cycling of DOX. The quinone
moiety of DOX accepts one electron from NAD(P)H to form a semiquinone that
quickly regenerates its parent quinone by reducing oxygen to form superoxide
(•O2-); NAD(P), nicotinamide adenine dinucleotide (phosphate); •O2-, superoxide
(Stěrba et al., 2013)
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Examples:

A

B

TMD1

TMD2
Pgp/MDR1 (ABCB1)
MRP4 (ABCC4)
MRP5 (ABCC5)
BSEP (ABCB11)
MDR3 (ABCB4)

TMD0 TMD1

TMD2
MRP1
MRP2
MRP3
MRP6
TMD1

C
BCRP (ABCG2)
ABCG5
ABCG8
Figure 1.2. Structures of three categories of ABC transporters. Schematic
representation of the predicted domain arrangement of (A) full length transporter;
(B) extended full length transporters with an extra transmembrane domain at the
N-terminus (TMD0), and (C) half transporters that require dimerization for full
function. ABC, ATP-binding cassette; CL, cytoplasmic loops.
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(a)

(b)

(c)

(d)

Figure 1.3. Proposed transport mechanism of ABC transporters.

(a)

Substrates interact with the TMDs from the intracellular face of the membrane.
(b) TMDs undergo a conformational change and 2 molecules of ATP bind to the
NBDs.

(c) ATP binding induces further conformational changes of TMDs,

resulting in substrate translocation. (d) ATP hydrolysis and transporter is reset
for substrate binding. TMD, transmembrane domain; NBD, nucleotide-binding
domains. (Dong et al., 2005)
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(1)

(3)

(2)

(4)

(5)

Figure 1.4. Substrates of MRP1. Shown are representative examples of the
endo- and xenobiotics (and organic anion metabolites) effluxed from cells by
MRP1 in either a glutathione (GSH)-independent or GSH-dependent manner.
MRP1 can transport glutathione, glucuronide or sulfate conjugated organic
anions (COA) (2) and unconjugated organic anions (UCOA) (1). (3) MRP1 also
co-transports GSH and substrates. (4) Some MRP1-mediated COA transport is
dependent upon the presence of GSH or its nonreducing derivative, SmethylGSH.

(5) In addition, GSH transport is stimulated by the presence of

drugs that are not themselves transported by MRP1. 4-HNE-SG, GSH conjugate
of 4-Hydroyx-2-nonenal (GS-HNE); AFB1-SG, GSH conjugate of aflatoxin B1epoxide; COA, conjugated organic anion; E217βG, 17β-estradiol 17-(β-Dglucuronide);

EA-SG,

GSH

conjugate

of

ethacrynic

acid;

GS-NO,

S-

nitrosoglutathione; GSSG, glutathione disulfide; LPI, lysophosphatidylinositol;

33

LTC4,

leukotriene

C4;

NNAL-OGluc,

(methylnitrosamino)-1-(3-pyridyl)-1-butanol;

β-O-glucuronide
PGA2-SG,

conjugate

GSH

of

4-

conjugate

of

prostaglandin A2; PGJ2-SG, GSH conjugate of 15-deoxy-12,14-prostaglandin J2;
pHAA-SG, GSH conjugate of acetaminophen; QO-SG, GSH conjugate of 4nitroquinoline 1-oxide; S-1-P, sphingosine 1-phosphate; S-MeGSH, S-methyl
GSH; UCOA, unconjugated organic anion. (Cole, 2014b)

34

4 H2O
GSSG

NAD(P)H

GPx

GR
NADP+

GSH
catalase

SOD
-

2•O2

H2O2

H2O + O2
NADP+

Trx Red
Prx

TrxR
NAD(P)H

Trx Ox
4 H2O
GSH

Grx Ox

GSSG

Grx Red

Figure 1.5. Redox signaling. When •O2- is formed, SOD converts two •O2- into
one molecule of H2O2 and one molecule of O2.

Catalase catalyzes the

decomposition of H2O2 into H2O and O2. GPx and Prx reduce H2O2 to H2O by
consumption of reduced GSH or reduced thioredoxin (Trx). Grx are oxidized by
substrates, and reduced non-enzymatically by GSH.

Gpx, glutathione

peroxidase; GR, glutathione reductase; Grx, glutaredoxin; Prx, peroxiredoxin;
SOD, superoxide dismutase; Trx, thioredixin; TrxR, thioredoxin reductase.
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GSH

GSH
+

H2O2

NAD(P)

GR

GPx

NAD(P)H

H2O + 1/2O2

GSSG

Figure 1.6. Redox cycling maintains cellular GSH/GSSG homeostasis
during oxidative challenge. Under oxidative stress, GSH detoxifies ROS to
form GSSG. The regeneration of GSH from GSSG is maintained by the GSSG
reductase system in a NAD(P)H dependent manner. GR: glutathione reductase;
GPx: glutathione peroxidase.
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A

B

Figure 1.7. Process of GSH synthesis. (A) In the first step of GSH synthesis,
an amide linkage is formed between cysteine and glutamate catalyzed by the
GCL. (B) Then, GSS catalyzes the reaction between glycine and the cysteine
carboxyl of γ-glutamylcysteine dipeptide to form GSH.
cysteine ligase; GSS, glutathione synthetase.
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GCL, γ-glutamate-

Figure 1.8. GSH degradation. GSH is transported out of the cell and broken
down by the membrane-bound ectoenzyme γGT, which removes the γ-glutamyl
moiety, and then by dipeptidases, which remove the glycine moiety.

The

resulting amino acids can be taken up by the cell and used for additional GSH
synthesis.

ATP, adenosine triphosphate; ADP, adenosine diphosphate; Cys,

cysteine; Glu, glutamate; Gly, glycine; Pi, inorganic phosphate; γGT, γ glutamyl
transpeptidase. (Wang and Ballatori, 1998)
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A
1. LH + X•

L• + XH

2. L• + O2

LOO•

3. LOO• + LH

B

LOOH + L•

PUFAs

antioxidant
s

lipid peroxidation

ROS, RNS,
free radicals

lipid hydroperoxides

decomposition

HNE, MDA
and other secondary products
Figure 1.9. Oxidative stress causes lipid peroxidation and HNE formation.
(A) Chain reaction of lipid peroxidation; (B) HNE is generated as a secondary
product of lipid peroxidation. HNE, 4-Hydroyx-2-nonenal; MDA, malondialdehyde;
PUFA, polyunsaturated fatty acids; RNS, reactive nitrogen species; ROS,
reactive oxygen species.
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Aldehyde
group

3
4
1
2

Alcohol group

Double bond

Figure 1.10. Three main functional groups of HNE: an aldehyde, a double
bond (alkene) between carbon C2 and C3, and a secondary alcohol at carbon C4.

HNE
adduct
of His

HNE
adduct
of Cys

HNE
adduct
of Lys

Figure 1.11. A linear depiction of HNE adducts with amino acids. HNE
adduction can take place by the 1,4-addition (Michael addition) of the
nucleophilic groups in cysteine (Cys), histidine (His) or lysine (Lys) residues of
the protein, respectively, onto the electrophilic double bond of HNE, giving an
increase in the protein's molecular mass by 156 Da with each molecule of HNE
being added.
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ALDH
HNA

HNE
AR
ADH

DHN

AR

GS-HNE

GS-DHN

Figure 1.12. Metabolism pathways of HNE.

ADH, alcohol dehydrogenase;

ALDH, Aldehyde dehydrogenase; AR, alcohol reductase; DHN, 1,4-dihydroxy-2nonene; GS-HNE, glutathione conjugate of 4-Hydroyx-2-nonenal; GS-DHN,
glutathione conjugate of 1,4-dihydroxy-2-nonene; HNA, 4-hydroxy-2-nonenoic
acid; HNE, 4-Hydroyx-2-nonenal. (Pappa et al., 2003)
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Table 1.1: Human ABC transporters subfamilies
Family

Members

Functions

ABCA

ABCA1 to ABCA12

Cholesterol efflux, phosphatidyl choline efflux, N-retinylidiene-PE efflux

ABCB

ABCB1 to ABCB11

Peptide transport, iron transport, Fe/S cluster transport, bile salt transport,
xenobiotics transport

ABCC

ABCC1 to ABCA13

Organic anion efflux, nucleoside transport, chloride ion channel, sulfonylurea
receptor, potassium channel regulation, xenobiotic transport
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ABCD

ABCD1 to ABCD 4

Very long chain fatty acids transport regulation

ABCE

ABCE 1

Elongation factor complex

ABCF

ABCF1 to ABCF3

Unknown function

ABCG

ABCG1 to ABCG 5

Cholesterol transport, sterol transport, toxin transport

Table 1.2: SNPs of Mrp1 correlated with anthracycline induced cardiotoxicity
Rs#

Mutation
(position)

Location
Type

Disease
Treated

Drug

Effect

Ref

rs45511401

2012 G>T
(nsSNP)

Gly671Val
Exon 16 (NBD1)

Non-Hodgkins
lymphoma

Doxorubicin

cardiotoxicity

Wojnowski et
al., 2005

rs3743527

C>T

3’-UTR

ALL (childhood)

Doxorubicin

cardiotoxicity

rs246221

825 T>C

ALL (childhood)

Doxorubicin

cardiotoxicity

rs4148350

G>T

Val275Val
Exon 8
intron 15

Pediatric cancer

Anthracycline

cardiotoxicity

Semsei et al.,
2012
Semsei et al.,
2012
Visscher
et al., 2012
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ALL, Acute lymphoblastic leukemia; Rs#, reference SNP ID number.
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Chapter Two

Loss of Mrp1 potentiates DOX-induced cardiotoxicity in mice

Overview of Study
Cardiotoxicity is one of the most severe side effects caused by anti-cancer
chemotherapy, including DOX.

Previously our laboratory reported that

expression of Mrp1 in cardiac sarcolemma increases in response to a single
injection of DOX in mice (Jungsuwadee et al., 2006).

Our laboratory also

reported that a single intravenous administration of DOX caused significantly
higher nuclear injury in Mrp1-/- mice heart compared to their WT littermates. In
this chapter, experiments were conducted to investigate the effects of chronic
DOX-induced cardiotoxicity in WT and Mrp1-/- mice and confirmed our prior
finding in mice treated acutely with DOX, and more importantly, demonstrated
the role of Mrp1 in protecting against DOX-induced cardiac dysfunction. The
health condition of these mice was monitored. Chronic DOX caused body weight
loss and hemotoxicity, and these adverse effects were significantly exacerbated
in Mrp1-/- vs WT mice. Using transthoracic echocardiography techniques, it was
found that DOX caused more severe left ventricle dysfunction in Mrp1-/- mice,
shown as significantly lower fractional shortening (FS) and ejection fraction (EF).
This pathological dysfunction was consistent with the measurements of heart
apoptosis and BNP expression in heart ventricle.

This study is the first to

demonstrate the protective effects of Mrp1 against chronic DOX-induced cardiac
dysfunction.
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Introduction
Doxorubicin (DOX) is an effective chemotherapeutic anthracycline used for a
variety of solid tumors and hematologic malignancies; however, its clinical use is
significantly limited by its dose-dependent cardiotoxicity (Minotti et al., 2004;
Octavia et al., 2012). The incidence of cardiomyopathy is 2.5 times higher in
cancer patients treated with DOX than that in untreated patients (Dolye et al.,
2005). It is well-established that the reactive oxygen species (ROS) generated
by DOX, which cycles between the quinone and semiquinone in cardiac
mitochondria, contribute significantly to cardiac pathology (Yen et al., 1996;
Gewirtz, 1999; Minotti et al., 2004). However, the self-regulation and defense
mechanisms of heart tissue in this process are still unclear.
Multidrug resistance-associated protein 1 (MRP1/ABCC1), a member of the
ATP-binding cassette (ABC) transporter protein superfamily, is ubiquitously
expressed in multiple tissues, including heart (Flens et al., 1996; Nies et al.,
2004). Mrp1 mediates the efflux of glutathione (GSH) and glutathione disulfide
(GSSG) as well as GSH, glucuronate and sulfate conjugated organic anions,
including leukotriene C4 (LTC4) and the GSH conjugate of 4-Hydroxy-2-nonenal
(GS-HNE) (Leier et al., 1994; Cole and Deeley, 1998; Renes et al., 2000; Leslie
et al., 2001; Jungsuwadee et al., 2012). Although Mrp1-/- mice have normal
fertility and viability, their ability to transport key endo- and xenobiotics is
compromised (Wijnholds et al., 1997, Yoshioka et al., 2009).
Accumulating case-control clinical studies have shown that several singlenucleotide polymorphisms (SNPs) of MRP1 gene are related to susceptibility to
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cardiotoxicity observed in cancer patients treated with anthracyclines, including
DOX (Wojnowski et al., 2005; Semsei et al., 2012; Visscher et al., 2012). These
SNPs may affect efflux of DOX itself, but also may modulate efflux of other
important endobiotics (Jungsuwadee et al., 2012). Thus, MRP1 could play an
important role in regulation of oxidative stress by effluxing GSH and GSSG as
well as GS-HNE (Cole, 2014a; Cole, 2014b; Jungsuwadee et al., 2012).
In the present study, we explored the effects of Mrp1 on DOX-induced
cardiotoxicity in mice. Although Mrp1 is highly conserved between human and
rodents with 88% sequence homology, the human isoform (MRP1) is able to
transport DOX, whereas murine Mrp1 has only a negligible ability to transport this
anthracycline (Stride et al., 1997). More specifically, a glutamic acid, which has a
negative charge, on TM14 in human MRP1 is critical to accomplish the transport
of DOX. This glutamic acid is substituted by a glutamine in murine Mrp1, with
loss of the negative charge, and also loss of the ability to transport DOX (Figure
2.1) (Zhang et al., 2001). Therefore, the Mrp1-/- mouse provides a good model
to study the role of Mrp1 in DOX cardiotoxicity separately from the effects of DOX
retention.

Here evidence is presented for the first time that chronic DOX

treatment caused more severe cardiac dysfunction in Mrp1-/- mice.

These

results provide novel insights into the role of Mrp1 in cardiac protection beyond
the ability to transport DOX.
Materials and methods
Animals and treatment
C57BL/6 (WT) mice and Mrp1-disrupted C57BL/6 (Mrp1-/-) mice, initially a
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gift from Dr. Gary Kruh, were backcrossed for more than ten generations,
littermates bred in-house and maintained in the Division of Laboratory Animal
Resources. All experiments complied with the requirements of the Institutional
Animal Care and Use Committee of the University of Kentucky (Lexington, KY).
The animal treatment protocols were based on studies demonstrating decreased
cardiac function following chronic treatment with DOX (Zhang et al., 2009). All
experiments used male mice 10 to 12-weeks old and weighing 25–35 g. DOX
(Pfizer, NY) was administered intraperitoneally at a dose of 3 mg/kg (Figure 2.2
protocol A) or 2 mg/kg (Figure 2.2 protocol B) body weight, or an equivalent
volume of saline, twice a week for 3 or 5 weeks, resulting in a cumulative DOX
dose of 18 (Protocol A) or 20 mg/kg (Protocol B). Hydration and nutritional gel
(72-07-5022, ClearH2O, Portland, ME) were provided to mice as supplements, 1
oz per 5 mice, and replaced every 2 days, in addition to pelleted food and water
throughout the treatment period. Animal body weight was recorded throughout
the experimental period.

Animals were euthanized and examined 48 h or 2

weeks after the last DOX treatment.

Complete blood count
Peripheral blood (∼20 µL) was collected from WT and Mrp1-/- mice 48 h and
2 weeks after the last DOX treatment (Protocol B) by sub-mandibular bleeding.
Blood cell parameters were obtained on the Hemavet 950FS automated
hematology analyzer (Drew Scientific, Dallas, TX).
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Transthoracic Echocardiography
Transthoracic echocardiography was performed with a Vevo 2100 HighResolution In Vivo Imaging System (Visual Sonics Inc., Toronto, Canada). The
mice were lightly anesthetized by isoflurane (0.5-1.5%) until the heart rate
stabilized at ~500 beats/min. With the use of the M-mode from parasternal shortaxis images, left ventricular end-diastolic dimension (LVIDs) and left ventricular
end-systolic dimension (LVIDs) were measured.

The percentage of left

ventricular fractional shortening (LVFS) was calculated as 100 X ((LVIDdLVIDs)/LVIDd). LV volume at end-diastole (LVEDV) was estimated as [7.0/(2.4 +
LVIDd)] X LVIDd3 and at end-systole (LVESV) as [7.0/(2.4 + LVIDs)] X LVIDs3.
Left ventricular ejection fraction (LVEF) was determined by using [(LVEDV LVESV)/ LVEDV] X 100%. Echocardiography was conducted by investigators
who were blinded to treatment group assignments and genotype.

Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL)
assay
The tip of the mouse heart ventricle was fixed in 10% formalin, embedded in
paraffin, 4 μm sections cut and stained using the ApopTag® Peroxidase In Situ
Apoptosis Detection Kit (S7100, Millipore) according to the manufacturer’s
instructions. Counterstaining with Mayer’s hematoxylin aided in the morphologic
evaluation of normal and apoptotic nuclei, in which normal nuclei were stained as
blue and apoptotic nuclei as brown. The number of TUNEL-positive cells was
quantitated using Aperio scanning image analysis of sections. DNase I treatment
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was carried out as the positive control.

Hydroxyproline Analysis
Heart ventricle tissue was ground with liquid nitrogen, and 10 mg tissue
powder, 100 µL of distilled water and 100 µL of concentrated HCl (10 N) added
to a glass vial with Teflon cap and hydrolyzed at 120°C for 24 h. Hydrolyzed
samples were transferred to a microcentrifuge tube and spun at 10,000 rpm for 3
min to remove hydrolyzed residue from the sample, and supernatants used for
the assay. Briefly, according to manufacturer's instructions (#6017, Chondrex,
Inc., Redmond, WA), samples were distributed to a 96-well plate, incubated with
chloramine-T solution at room temperature for 20 minutes and incubated with
dimethylaminobenzaldehyde

(DMAB)

solution

for

30

minutes

at

60°C.

Absorbance was measured at 530 nm on a spectrophotometer (Molecular
Devices, CA).

Hydroxyproline levels were calculated according to standards

provided. The results were expressed as total collagen (µg) /heart tissue (mg),
assuming that collagen contains an average of 13.5% hydroxyproline.

RNA extraction and real-time quantitative PCR (qRT-PCR)
Total RNA was isolated from heart ventricles using Trizol Reagent (Sigma)
according to the manufacturer’s instructions, except that DNase I treatment was
incorporated.

RNA concentrations were determined using NanoPhotometer

(Implen GmbH, München, DE). Total RNA (2 μg) was converted into cDNA with
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, USA) and
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the mixture diluted without purification in sterile water and used for qRT-PCR
analysis.

mRNA expression of specific genes was quantified using the

LightCycler® 480 Real-Time PCR System (Roche Applied Science, Mannheim,
Germany). Forward and reverse primers used are as follows: brain natriuretic
peptide

(BNP)

5’-GTCAGTCGTTTGGGCTGTAAC-3’

AGACCCAGGCAGAGTCAGA-3’

(reverse);
(forward)

GCAATTATTCCCCATGAACG-3’

18S

(forward)

and

rRNA
and

5’5’5’-

GGGACTTAATCAACGCAAGC-3’ (reverse). These primers were ordered from
Integrated DNA Technologies (Coralville, IA, USA); Universal probe library (UPL)
probes #71 (BNP), #48 (18S rRNA) were obtained from Roche Applied Science.
The qRT-PCR reactions were performed in duplicate in 15 μL reaction volume
containing 2 μL 1:10 diluted cDNA and 1× LightCycler 480 Probes Master Mix.
18S rRNA was selected as reference gene, for which cDNA samples were
diluted 1:4000.

Data were evaluated by calibrator-normalized relative

quantification with efficiency correction using the Light Cycler® 480 software
version 1.5 (Roche Applied Science, Mannheim, DE). The software calculated
the relative amount of the target gene to the reference gene based on the
crossing points.

Statistical analysis
All data are expressed as the mean ± SE for n = 5 to 12 mice per group, as
detailed in the Figure Legends. For body weight data, a linear mixed model was
considered with fixed effects of treatment group, day and their interaction and
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random effects of both the intercept and slope. The slope of weight loss and the
weight change at the end of the treatment were compared between two
treatment groups based on the linear mixed model.

For data from other

experiments, firstly a Bartlett’s test is used to test homogeneity of variance
across all groups. If the Bartlett’s test result was not significant, further statistical
analysis was performed using a one-way ANOVA with post hoc analysis by the
Newman-Keuls method.

If the Bartlett’s test result was significant, further

statistical analysis was performed using Welch’s t-tests for pairwise comparisons
between groups of interest with the Bonferroni correction for multiple comparison
adjustment.

Results
Chronic DOX administration decreased mouse body weight and heart
weight
Mrp1-/- mice and their WT littermates were treated with either 3 mg/kg body
weight, twice a week for 3 weeks (Figure 2.3 protocol A), or 2 mg/kg body weight,
twice a week for 5 weeks (Figure 2.3 protocol B). DOX markedly decreased
body weight of WT and Mrp1-/- mice; after DOX treatment was discontinued and
during the 2-week recovery period, body weight stabilized and began to recover
in all DOX treated animals. Comparison of the slope of weight loss for DOXtreated Mrp1-/- vs WT mice and the weight change in the two groups at the end
of the treatment (day 21 and 35 for the 3 and 2 mg/kg DOX treatment groups,
respectively) showed that the magnitude of the decrease was significantly larger
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in Mrp1-/- compared to WT mice (p < 0.001 for both comparisons). With the 3
mg/kg DOX treatment, 4 of 13 Mrp1-/- mice were euthanized due to severe body
weight loss (22-25% of initial body weight) before the last day of the experimental
period. Thus, for subsequent experiments, except for the TUNEL assay, data
were acquired using the lower DOX dose (2 mg/kg) treatment (Protocol B). DOX
treatment also significantly decreased heart weight in both genotypes (Figure
2.4).

Effects of chronic DOX administration on blood counts
Chronic DOX treatment (2 mg/kg) significantly decreased white blood cell
(WBC) and lymphocyte (LY) counts in both genotypes 48 h after the last DOX
treatment (Figure 2.5A and 2.5B).

Two weeks later, the WBC, including LY

counts, had recovered in WT mice, but remained significantly decreased in
Mrp1-/- mice (p < 0.05) (Figure 2.5C and 2.5D).

Cardiac function after chronic DOX administration
To determine whether cardiac contractile function was affected by chronic
DOX

administration,

LVIDd

and

LVIDs

were

assessed

by

in

vivo

echocardiography 2 weeks after the last DOX treatment (2 mg/kg), and LVFS
and LVEF calculated. Figure 2.6A shows representative echocardiograms of WT
and Mrp1-/- mice after saline or DOX administration. There were no significant
differences in LVFS and LVEF between WT and Mrp1-/- saline treated mice
(Figure 2.6B), indicating that Mrp1-/- mice had normal basal contractile function.
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DOX treatment increased both LVIDd and LVIDs and decrease LVPWd and
LVPWs in WT and Mrp1-/- mice (Figure 2.6 B - E). Importantly, DOX significantly
reduced LVFS and LVEF in Mrp1-/- mice, while there were no significant
changes in these values in WT mice (Figure 2.6F and 2.6G).
B-type Natriuretic Peptide (BNP) is a cardiac hormone secrected from the
ventricles of the heart in response to ventricular volume and pressure overload.
Thus, elevated BNP expression was used as a heart failure marker. Here, BNP
mRNA expression was found to be significantly higher in DOX treated Mrp1-/mouse heart compared to WT mouse heart (Figure 2.6H). This was consistent
with the cardiac dysfunction observed in DOX treated Mrp1-/- mice. These data
clearly demonstrate that loss of Mrp1 exacerbated DOX-induced cardiac
dysfunction.

DOX-induced apoptosis in mouse heart
The effects of Mrp1 on DOX-induced cell apoptosis in the heart was
investigated using TUNEL staining to evaluate heart sections. Cells containing
intensive TdT-positive staining in the nuclei were considered apoptotic. As a
result, DOX treatment (3 mg/kg) increased apoptosis in mouse hearts of both
genotypes, however, Mrp1-/- hearts showed significantly more extensive (~3.5
fold higher) TUNEL staining nuclei compared to WT mice hearts (p < 0.05)
(Figure 2.7), consistent with the more severe cardiotoxicity seen with
measurements of ventricular systolic function.
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Chronic DOX administration increased heart ventricular fibrosis
Since DOX has been reported to induce cardiac fibrosis (Zhu et al., 2008; Li et
al., 2006), the mouse ventricular fibrosis was examined by quantitating the
collagen level. As shown in Figure 2.8, saline treated WT and Mrp1-/- mice heart
had similar collagen levels, while DOX treatment significantly increased
ventricular collagen level in both WT and Mrp1-/- mice. However, no significant
difference in the collagen level was found between genotypes.

Discussion
The key finding in the present study is that global deletion of Mrp1
potentiates

DOX-induced

cardiac

toxicity

in

mice

as

measured

by

echocardiography, apoptosis and the ventricular dysfunction marker BNP. DOX
is an anti-tumor anthracycline that is effective in treating a wide variety of cancers,
but produces dose-limiting cardiac toxicity.

Although all of the factors

contributing to the mechanism for DOX-induced cardiotoxicity are not known, it is
well accepted that oxidative stress contributes significantly to DOX-induced heart
failure (Yen et al., 1996; Minotti et al., 2004; Kang et al., 2007). Our group and
others have shown that adduction of cardiac proteins with HNE, a toxic product
of lipid peroxidation induced by oxidative stress, is increased in DOX treated
mice (Renes et al., 2000; Jungsuwadee et al., 2006). Additionally, sarcolemmal
membrane vesicles from WT mouse heart transport GS-HNE, but this activity is
absent in such vesicles from Mrp1-/- mice (Jungsuwadee et al., 2009).

In

addition, 72 h after a single dose of DOX (15 mg/kg body weight, iv) there is
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significantly more nuclear injury in Mrp1-/- compared to WT hearts (Deng et al.,
submitted).

Based on these findings, we hypothesized that Mrp1 protects

against DOX-induced cardiac dysfunction.
Here the previous ﬁndings were extended to assess whether loss of Mrp1
affects cardiac function following DOX treatment. The data show that chronic
DOX treatment caused a more severe left ventricle dysfunction in Mrp1-/- mice,
presenting as decreased LVFS and decreased LVEF.

These pathological

changes were also consistent with the higher BNP expression and more
apoptotic nuclei observed in Mrp1-/- mouse heart.

These data further

demonstrated that loss of Mrp1 potentiated DOX-induced cardiac dysfunction in
addition to the nuclear damage in heart, even though Mrp1-/- mice heart have
higher GSH levels due to the loss GSH efflux via Mrp1 (Deng et al., submitted).
Together, these data strongly support the hypothesis that Mrp1 protects the heart
against DOX toxicity in vivo.
Several ABC transport mRNA/proteins have been reported to be present to
various degrees in heart (Couture et al., 2006), and could contribute to efflux of
DOX.

Pgp (Abcb1a, Abcb1b), BCRP (Abcg2) and Mrp2 (Abcc2) were

demonstrated to contribute to DOX resistance by mediating its efflux (Couture et
al., 2006; Vlaming et al., 2006; Natarajan et al., 2012). In addition, Mrp4 (Abcc4)
is able to efflux GSH and GSSG (Ballatori et al., 2005). It has been reported that
there is no/very low expression level of Abcc2 in heart (Couture et al., 2006).
Also we did not detect the protein expression of Abcg2 in heart tissue. To rule out
potentially altered, compensatory expression of other transporters in the heart of
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Mrp1-/- mice, we measured the protein expression of Abcb1 and Abcc4 2 weeks
after the last dose of DOX or saline.

These data show that none of these

transporters showed a significant difference between WT and Mrp1-/- mice heart
following treatment with saline or DOX (Figure 2.9).
Finally, decreased recovery from hematopoietic toxicity was seen in Mrp1-/mice following DOX treatment.

This transient myelosuppression, shown as

decreased WBC counts and LY counts in DOX treated mice, is probably caused
by the suppression or apoptosis of hematopoietic progenitor cells. But how Mrp1
affects the replenishment of these blood cells is not clear. Another key finding
was that DOX treatment caused a more severe body weight loss in Mrp1-/- mice.
This is likely associated with reduced food consumption, since DOX causes a
loss of appetite in DOX-treated cancer patients. It is also well-known that DOX
causes dose-limiting gastrointestinal injury due to its toxic effect on intestinal
epithelium, including the rapidly dividing stem cells located at the base of the
intestinal crypts.

The apoptosis in intestinal epithelium and the loss of villi

throughout the small intestine could compromise digestive and absorptive
capacities, finally causing severe body weight loss in mice (Ijiri and Potten, 1987).
However, since these Mrp1-/- mice are constitutive knockout animals, we could
not determine whether the intestine or other organs were primarily responsible
for this differential extent of body weight loss between WT and Mrp1-/- mice.
In summary, loss of Mrp1 potentiates DOX-induced cardiotoxicity, showing a
severe ventricular dysfunction and cellular apoptosis in heart tissue.

These

studies are the first to document a protective role of Mrp1 in DOX-induced
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cardiotoxicity and may provide critical information regarding the potential adverse
sequelae of introduction of MRP1 inhibitors as adjuncts to clinical chemotherapy
of multidrug resistant tumors.
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Figure 2.1. Murine Mrp1 does not transport DOX due to critical amino acid
differences with human MRP1.

The figure shows the predicted topology of

human and murine MRP1/Mrp1 with 17 TM helices. An expanded view of the
region encompassing TM helix 14 is illustrated in the bottom half of the figure.
The amino acids shown in the expanded view are those found in human MRP1.
Residues in open circles are identical in the murine and human proteins.
Residues that are different between the two proteins are indicated by shaded
circles, and the amino acids present in murine Mrp1 at the equivalent positions
are shown to the side. L, leucine; M, methionione; K, lysine; E, glutamic acid; V,
valine; F, phenylaline; G, glycine; I, isoleucine; D, aspartic acid; N, asparagin; S,
Serine; P, proline; Q, glutamine; CL: cytoplasmic loops.
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Protocol A
Week

1

DOX
2x
(3 mg/kg, i.p.)

2

3

5

2x

2x

End

Total Cumulative Dose: 18 mg/kg

Protocol B
Week

1

2x
DOX
(2 mg/kg, i.p.)

2

3

4

5

7

2x

2x

2x

2x

End

Total Cumulative Dose: 20 mg/kg

Figure 2.2. Chronic DOX treatment protocols. Protocol A: WT and Mrp1-/mice were administrated intraperitoneal DOX, 3 mg/kg body weight, or an
equivalent volume of saline, twice a week for 3 weeks, resulting in a cumulative
dose of 18 mg/kg DOX. Protocol B: WT and Mrp1-/- mice were administrated
intraperitoneal DOX, 2 mg/kg body weight, or an equivalent volume of saline,
twice a week for 5 weeks, resulting in a cumulative dose of 20 mg/kg DOX.
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A

B

Figure 2.3. Body weight change during chronic DOX treatment. WT and
Mrp1-/- mice were administrated intraperitoneal DOX with protocol A (A) or
protocol B (B), and maintained for an additional two weeks (“recovery”); animal
weight was monitored throughout. Arrow: one mouse was sacrificed on each of
the indicated days due to body weight loss (loss of 22 - 25% of initial body
weight). Values are mean ± SE. (Panel A, n = 12; Panel B, n = 12 before day 35
and n = 6 after day 35)
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Figure 2.4. Heart weight change after chronic DOX treatment.

WT and

Mrp1-/- mice were administered intraperitoneal DOX with protocols A (A) or B (B).
Two weeks later, the hearts were removed immediately and weighed. Each bar
represents the mean ± SE. (In figure A, n= 12 for saline treated group; n=12 for
DOX treated WT mice; n=10 for DOX treated Mrp1-/- mice; in figure B, n=6 for
each group, *, p < 0.05 DOX vs. saline of the same genotype by Newman-Keuls
multiple comparison test after one-way ANOVA)

61

Figure 2.5. The effects of DOX on white blood cell (WBC) and lymphocyte
(LY) counts.

Mice were treated with protocol B, and WBC and LY counts

measured 48 h (A and B) and 2 weeks (C and D) after the last DOX dose.
Decreased WBC and LY counts were observed in both WT and Mrp1-/- mice at
48 h after the last DOX dose, and had recovered two weeks later in WT mice, but
remained depressed in Mrp1-/- mice. K/µL, 1000 cells per microliter. Each bar
represents the mean + SE. (n=8 for saline treated group; n=12 for DOX treated
group, *, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1-/- vs.
respective WT mice by Newman-Keuls multiple comparison test after one-way
ANOVA).
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B

C

D

E

F

G

63

H

Figure 2.6. Chronic DOX treatment leads to more severe systolic
dysfunction in Mrp1-/- mice vs. WT mice. Mice were treated with protocol B,
and cardiac function assessed through M-mode transthoracic echocardiography.
(A) Representative M-mode echocardiogram of left ventricular (LV) wall motion;
(B) LVIDd, (C) LVIDs, (D) LVPWd, (E) LVPWs, (F) Fractional shortening, (G)
Ejection fraction and (H) mRNA expression of BNP analyzed by qRT-PCR 2
weeks after chronic saline or DOX treatment. Each bar represents mean ± SE.
(n=8 for saline treated group; n=12 for DOX treated group; *, p < 0.05 DOX vs.
saline of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT mice by
Newman-Keuls multiple comparison test after one-way ANOVA). LVIDd: left
ventricular end-diastolic dimension; LVIDs: left ventricular end-systolic dimension;
LVPWd, left ventricular diastolic posterior wall thickness; LVPWs, left ventricular
systolic posterior wall thickness.
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E

Figure 2.7. Apoptosis in mouse myocardium.

Mice were treated using

protocol A, and apoptosis from mouse myocardium detected by TUNEL
(Terminal deoxynucleotidyl transferase dUTP nick end labeling assay) staining.
Representative photomicrographs are shown demonstrating TUNEL staining of
heart sections from saline treated WT (A), DOX treated WT (B), saline treated
Mrp1-/- (C), and DOX treated Mrp1-/- mice (D).

TUNEL-positive cells are

indicated by brown staining, and the TUNEL-positive nuclei are indicated by
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arrows. (E) Histogram showing the quantitative analysis of TUNEL-positive cells.
Each bar represents mean ± SE (n=6 for saline treated group; n= 10 for DOX
treated WT mice, n=8 for DOX treated Mrp1-/- mice. *, p < 0.05 DOX vs. saline
of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT mice by Welch’s ttest.)

*

*

Figure 2.8. DOX increased collagen level in mouse heart. Mice were treated
using protocol B, and hydroxyproline levels in mouse heart tissue measured.
The results are expressed as total collagen/heart tissue, assuming that collagen
contains an average of 13.5% hydroxyproline. Each bar represents the mean ±
SE. (n = 8, *, p < 0.05 DOX vs. saline of the same genotype by Newman-Keuls
multiple comparison test after one-way ANOVA).
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A

B

Figure 2.9. Protein expressions of Abcb1 and Abcc4 in mouse heart. Mice
were treated with protocol B, and the protein level of Abcb1 and Abcc2 were
measured 2 weeks after the last dose of DOX by real time PCR.
represents the mean ± SE. (n = 3)
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Chapter Three

Mrp1 protects both cardiomyocytes and cardiac fibroblasts against DOX
cytotoxicity

Overview of Study
The studies in chapter 2 demonstrated that loss of Mrp1 potentiates chronic
DOX treatment induced cardiotoxicity in mice, presenting more severe left
ventricle dysfunction and greater cell apoptosis in Mrp1-/- mouse heart. Here, to
extend the findings of Mrp1’s cardiac protective role to a cellular level, and
identify the specific function of Mrp1 in different cell types in heart, the effects of
Mrp1 on DOX cytotoxicity in cardiomyocytes (CM) and cardiac fibroblasts (CF)
was further investigated. Neonatal mouse CM and CF, isolated from WT and
Mrp1-/- 1-3 days old pups, were treated with DOX (0.3 - 4 μM) for various times.
DOX significantly increased Mrp1 mRNA and protein expression level in both CM
and CF cultures. The methyl thiazol tetrazolium (MTT) assay showed that CM
and CF derived from Mrp1-/- mice demonstrate a greater decrease in cell viability
after DOX treatment.

Further studies suggested that there was more cell

apoptosis and DNA damage in DOX treated Mrp1-/- cells, presenting as higher
caspase 3 cleavage, PARP cleavage and γH2.AX expression vs WT cells.
Taken together, these results indicate that Mrp1 protects both CM and CF
against DOX induced cytotoxicity.
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Introduction
Cardiotoxicity is one of the most serious side effects in DOX treated cancer
patients. Identifying the gene(s) involved in normal hearts’ defense against this
toxicity and understanding the mechanisms will be very helpful to find the
potential approaches to prevent or alleviate this dose-limiting toxicity. Our in vivo
studies demonstrate that loss of Mrp1 potentiates chronic DOX treatment
induced cardiotoxicity in mice, with Mrp1-/- mice exhibiting more nuclear injury
after a single DOX injection and more severe cardiac dysfunction and greater
heart apoptosis following chronic DOX treatment.

Here, to extend the bases of

Mrp1’s cardiac protective role to a cellular level, the role of Mrp1 in DOX toxicity
in cardiomyocytes (CM) and cardiac fibroblasts (CF) was further evestigated.
CM and CF form the two largest cell populations in heart, while other cell types,
such as endothelial or vascular smooth muscle cells, represent comparatively
small populations. CMs are the major cells that make up the atria and ventricles
of the heart, and account for more than 50% of total cell number in heart.
During fetal life, cardiomyocyte DNA synthesis is associated with cell proliferation,
and after birth (up to approximately neonatal day 3) a second DNA synthesis
phase is associated with binucleation.

After that, cardiac growth involves

increasing the size of the myocytes without substantial increases in cell number
(Woodcock et al., 2005). The low proliferative capacity of adult CMs means that
loss of working CMs in adult heart cannot be replaced and must be compensated
by increased work load of the remaining myocytes; otherwise, cardiac
dysfunction will develop.

This also partially explains why the heart is so
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susceptible to DOX toxicity compared to other tissues with better selfregeneration capacity.

The CMs are able to shorten through the interaction

between myofilament proteins actin and myosin, and these cells must be able to
shorten and lengthen properly to maintain normal cardiac structure and function.
A rapidly expanding body of evidence indicates that CM death by apoptosis and
necrosis is an important mechanism of DOX-induced cardiomyopathy (Zhang et
al., 2009; Octavia et al., 2012).
CFs are the most abundant non-cardiomyocytes within the heart. They are
found throughout cardiac tissue surrounding CM and bridging ‘the voids’ between
myocardial tissue layers. Compared to CM, the understanding of CF function is
much less. CFs provide a supporting structure to the healthy heart, contribute to
myocardial structure, cell signaling, and electro-mechanical function in healthy
myocardium (Camelliti et al., 2005).

Beyond their very important roles in

maintaining myocardial function under normal condition, CFs also contribute to
adverse cardiac remodeling during pathological conditions, such as hypertension,
myocardial infarction, and heart failure (Souders et al., 2009; Shi et al., 2011).
Upon cardiac injury, CFs may proliferate and secret extracellular matrix and
growth factor, leading to scar formation, cardiac fibrosis, myocardial stiffening
and finally, cause cardiac dysfunction. Emerging research indicates that CFs are
involved in arrhythmia initiation and maintenance by affecting electrical
propagation (Kamkin et al., 2005).
The previous study in our laboratory and the data in Chapter 2 showed the
cardiac protective function of Mrp1 in DOX treated mice (Deng et al., submitted).
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Here, to further extend our findings to a cellular level, the effects of Mrp1 on DOX
cytotoxicity was further investigated in the two major cell populations in heart: CM
and CF.

The results showed that in neonatal CM and CF cultures, DOX

increased Mrp1 expression at both mRNA level and protein levels. CM and CF
derived from Mrp1-/- mice were more sensitive to DOX toxicity, presenting lower
cell survival, more cell apoptosis and more DNA damage.

These data

demonstrated that Mrp1 protects both CM and CF against DOX toxicity.

Materials and methods
Neonatal mouse CM/CF isolation and culture
C57BL/6 (WT) mice and Mrp1-disrupted C57BL/6 (Mrp1-/-) mice were
backcrossed for more than ten generations.

Experiments complied with the

requirements of the Institutional Animal Care and Use Committee of the
University of Kentucky (Lexington, KY).

Primary CM and CF were obtained

from Mrp1-/- neonatal mice and their WT littermates at 1–3 days of age. Mice
were sacrificed by cervical dislocation, hearts were removed aseptically with the
ventricles only retained and maintained in cold Hanks’ balanced salt solution
(HBSS) without Ca2+ and Mg2+.

The ventricles were washed with the same

HBSS and minced into small fragments that were subjected to enzymatic
digestion in the HBSS with collagenase type 2 (Worthington Biochemical Corp.,
Lakewood, NJ). Serial cycles of agitation were performed. After each cycle, the
supernatant (containing the isolated cells) was removed and FBS added to a final
concentration of 10%, the resulting mixture centrifuged for 10 min at 100 g, and
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then the cells resuspended in DMEM with 10% FBS (v/v), 100 units/ml penicillin,
and 100 μg/ml streptomycin (GIBCO, Grand Island, NY). Cells were preplated
for 2 h at 37°C, to obtain CM and non-myocyte cells, predominantly CF. For CM
culture, 100 μmol/L Bromodeoxyuridine (Sigma Chemical Co.) was added during
the first 48 h to prevent proliferation of nonmyocytes. CM purity was tested by
staining

with

antibody

to

cardiac-sarcomeric

actin

according

to

the

manufacturer’s instructions (Sigma Chemical Co). CM purity averaged >95%
when examined after 48 h of culture. CF cultures were examined for positivity of
expression of vimentin by immunofluorescence (Figure 3.1).

Mouse anti-

vimentin mAb (sc73259) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).

CF cultures were used for experiments after two passages to

eliminate other nonmyocytes

Methyl thiazol tetrazolium (MTT) assay
The cytotoxicity of DOX was determined by the MTT test. WT and Mrp1-/- CM or
CF cells were seeded and grown in a 96-well plate at 37°C in a 5%
CO2 saturated atmosphere overnight. To develop a dose-response curve, DOX
stock solution (2 mg/ml, Pfizer, NY) was dissolved in culture medium to final
concentrations of 0 - 4 µM, and was incubated with cells in culture for 3 h, after
which the media containing DOX was removed. Cells were rinsed once with 1×
PBS, and finally incubated with fresh media for an additional 48 h. The MTT
assay was performed according to the manufacturer’s instructions (CellTiter 96
Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI). The
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absorbance at 480 nm was measured for each well by SpectraMax M5 multidetection reader (Molecular Devices, CA). The absorbance of untreated control
cells was taken as 100% viability and the values of treated cells were calculated
as a percentage of control. The data are represented as mean ± SE from 3
independent experiments.

Measurement of DOX concentration in cells
WT and Mrp1-/- CM or CF cells (106) were seeded and grown in a 12-well
plate at 37°C in a 5% CO2 saturated atmosphere overnight. Cells were treated
with 30 µM DOX. Following 1 h of incubation, cells were washed three times with
PBS and incubated with fresh DMEM medium for the indicated time. Finally, the
cells were washed three times with PBS and incubated in 75% acidified (0.75 N
HCl) isopropanol with 1% Triton X-100 and shaken for 30 min at room
temperature. The absorbance of the supernatant was read using a fluorescence
spectrofluorometer at wavelengths of Ex=470 nm and Em=590 nm. The value of
DOX accumulation within the cells was calculated according to the standard
curve.

RNA extraction and real-time quantitative PCR (qRT-PCR)
Total RNA extraction, cDNA preparation and qRT-PCR were conducted as the
method description in Chapter 2. PCR primers for Mrp1 are as follows: Mrp1 5’tgtgggaaaacacatctttga-3’ (forward) and 5’-ctgtgcgtgaccaagatcc-3’ (reverse); 18S
rRNA

5’-gcaattattccccatgaacg-3’

(forward)
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and

5’-gggacttaatcaacgcaagc-3’

(reverse).

Universal ProbeLibrary probes #105 (Mrp1), (18S rRNA) were

obtained from Roche Applied Science.

Immunoblot Assay
Protein concentrations were determined with the bicinchoninic acid protein
assay (Pierce, Rockford, IL). Protein samples were fractionated on a 4% to 12%
SDS-PAGE

gel

(EC6038BOX,

Life

nitrocellulose (Whatman, Stanford, ME).

Technologies)

and

transferred

to

The blots were incubated with the

primary antibody diluted in TBS/5% nonfat milk/0.1% Tween 20 at 4⁰C overnight,
then washed in TBS/0.1% Tween 20, and subsequently incubated with
horseradish peroxidase (HRP)-labeled secondary antibody in TBS/5% nonfat
milk/0.1% Tween 20. Chemiluminescence detection was done using Enhanced
Chemiluminescence Plus (RPN2236, GE Healthcare, UK).

Antibodies were

obtained as follows: rat anti-Mrp1 mAb (801-007-c250; Alexis, San Diego, CA),
rabbit anti-GAPDH pAb (sc-25778) and rabbit anti-actin pAb (sc-1616-R Santa
Cruz Biotechnology, Santa Cruz, CA), rabbit anti-PARP pAb (#9542), rabbit anticleaved caspase3 pAb (#9661) and rabbit anti–phospho-histone H2A.X (γH2A.X)
pAb (Ser139) (#9718) from Cell Signaling (Beverly, MA, USA), anti-rat Ig-HRP,
anti-rabbit Ig-HRP and anti-mouse Ig-HRP from Amersham Biosciences
(Piscataway, NJ).

Statistical analysis
All data are expressed as the mean ± SD for n = 3 to 6 per group, as detailed
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in the Figure Legends. In studies comparing two groups, statistical analysis was
performed with the Student’s t-test. In studies comparing multiple groups to the
same control group, statistical analysis was performed with one-way ANOVA
followed by Dunnett's post-test. In studies comparing more than two groups,
statistical analysis was performed with one-way ANOVA followed by NewmanKeuls multiple comparison test.

Results
DOX upregulates Mrp1 expression in CM and CF
To examine the effect of DOX on expression of Mrp1, CM and CF were
isolated from WT neonatal mouse heart tissue and treated with DOX for 24 h,
then expression of Mrp1 analyzed by Real-time PCR and Western blotting. As
shown in Figure 3.2, Mrp1 was constitutively present in CM and CF. Moreover,
DOX treatment significantly increased both Mrp1 mRNA (Figure 3.2A) and
protein expression (Figure 3.2C) in CM in a concentration-dependent manner. A
similar pattern was also observed in CF cultures (Figure 3.2B and Figure 3.2D).
GAPDH was used as a protein loading control, as the expression of GAPDH did
not change with DOX treatment. These results showed that DOX enhanced
Mrp1 expression in cultured neonatal mouse CM and CF, implying that this
protein could be involved in the cellular response to DOX.

Effect of Mrp1 on DOX-induced caytotoxicity
To characterize the role of Mrp1 in DOX resistance in a cell type specific
manner, cytotoxicity of DOX in WT and Mrp1-/- CM and CF was measured by
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MTT assay.

As shown in Figure 3.3A, after 3 h of DOX treatment following

incubation with DOX-free media for another 48 h, 0.3, 1 and 3 µM DOX
decreased viability, shown as mean ± SD, to 64±3%, 35±3% and 11±2%,
respectively, in Mrp1-/- CM, compared to 75±2%, 52±6% and 25±5% viability in
WT (p < 0.05). Similar experiments in CF cultures demonstrated again that CF
isolated from Mrp1-/- mice showed enhanced DOX toxicity (Figure 3.3B). The
expression of Mrp1 was only detected in WT cells but not Mrp1-/ cells. These
results indicated that Mrp1 protects both CM and CF against DOX cytotoxicity.

Effect of Mrp1 on DOX-induced cell apoptosis and DNA damage
In order to understand the mechanism of cell death, apoptosis-related proteins
were chracterized in WT and Mrp1-/- CM and CF. DOX treatment increased
PARP cleavage, caspase3 cleavage, and these increases were significantly
greater in Mrp1-/- CM compared to WT CM (Figure 3.4A). Similar results were
observed in CF cultures (Figure 3.4B).
The DNA damage was further assessed by quantitating expression of γH2AX.
The increased expression of γH2AX was observed at early time points and
continuously increased over time (0, 3, 6 and 9 h after treatment with DOX)
(Figure 3.5A).

Consistent with the results obtained by measure of PARP

cleavage and caspase 3 cleavage, γH2AX expression was statistically
significantly higher in Mrp1-/- CM compared to WT CM at 24 h after DOX
treatment (Figure 3.5B). Similar results were observed in CF cultures (Figure
3.5C and D). These results indicated greater apoptosis and DNA damage in
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Mrp1-/- CM and CF following DOX treatment compared with WT cells.
Although no evidence has shown that murine Mrp1 is able to transport DOX,
and in our previous study in mouse model, there is no significant difference of
DOX concentration between WT and Mrp1-/- mouse heart tissue at 3, 6 12 h
after a single intravenous administration of 15 mg/kg DOX (Deng et al,
submitted), the intracellular DOX accumulation in WT and Mrp1-/- cells was
further examined. As shown in Figure 3.6, there is no significant difference in
DOX intracellular retention between genotypes.

These data ruled out the

possibility of different intracellular DOX accumulation as the cause of the different
susceptibility to DOX in WT and Mrp1-/- cells. Because fluorescence was used
as the method of detection, fluorescent DOX metabolites may be contributing to
the total DOX concentration.

Discussion
DOX is effective in treating a wide variety of cancers, but produces dosedependent cardiac toxicity. Our group has shown that loss of Mrp1 in C57BL
mice potentiates acute DOX treatment induced heart nuclear injuries and chronic
DOX treatment-induced cardiac toxicity, including impaired left ventricular
systolic function and increased heart apoptosis (Deng et al., submitted; Chapter
2). The key finding in the present study is that deletion of Mrp1 potentiates DOXinduced toxicity in both CM and CF in a dose-dependent manner.
It is well known that the heart is comprised of a syncytium of CM and
surrounding nonmyocytes, the majority of which are CF. These two types of cells
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are highly interspersed in the myocardium and more and more evidence shows
that bidirectional cross talk between CM and CF plays important roles in
determining cardiac mechanical and electrical function in both normal and
diseased hearts. Therefore, this current study investigated how Mrp1 affects
DOX toxicity in these two different cells types.
Mrp1 was consistently expressed in cultured neonatal mice CM and CF, and
DOX treatment increased Mrp1 expression in a dose-dependent manner. More
importantly, Mrp1-/- cells were more sensitive to DOX-induced cytotoxicity,
showing a lower cell survival, higher caspase 3 cleavage, PARP cleavage and
higher γH2AX expression. These data clearly demonstrated that Mrp1 protects
both CM and CF against DOX toxicity, and also agreed with the results in
Chapter 2 showing a cardiac protective function of Mrp1 in the chronic DOXtreated mouse model. However, beyond the apoptosis and DNA damage, it is
possible that other mechanisms are involved in the protective effects provided by
Mrp1, based on the physiologic function of CM and CF. For example, a large
body of evidence shows that beyond the maintenance of normal structure and
function of the heart (Souders et al., 2009), CF serve as a source of mitogens,
extracellular matrix proteins, growth factors, and cytokines that could affect the
phenotype of CM. In addition, crosstalk between CF and CM is important for
both cardiac development and remodeling in response to injury (Ottaviano et al.,
2011). How Mrp1 could attribute to this communication between CM and CF
needs to be further studied.
Transcriptional regulation of Mrp1 upon treatment with DOX has been shown
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to involve many transcription factors, including Sp1, antioxidant response
element (ARE), and the JNK pathway.

Oxidative stress induces nuclear factor-

like 2 (Nrf2) translocation from the cytosol to the nucleus and binding with ARE,
and finally induce the transcription of Mrp1 and antioxidative genes (Hayashi et
al., 2003; Itoh et al., 2003; Nguyen et al., 2005). Our laboratory have shown that
upon DOX treatment of mice, Mrp1 expression in sarcolemma increases within 6
h and remains elevated for 24 h (Jungsuwadee et al., 2006). In this study, DOX
treatment significantly induced Mrp1 mRNA and protein expression in both CM
and CF in a dose-dependent manner.

Induction of Nqo1 and HO-1, two typical

downstream genes of the Nrf2 pathway, was also observed in CM and CF after
DOX treatment (data shown in Chapter 4). These data imply that in CM and CF,
Mrp1 expression is increased by the activation of the Nrf2 pathway under DOXinduced oxidative stress.
In summary, the key finding of this in vitro study is that loss of Mrp1
potentiates DOX cytotoxicity in CM and CF culture, presenting as more severe
apoptosis and DNA damage. It confirms the cardiac protective function of Mrp1
in vivo as shown in Chapter 2.

Taken together, these data provide strong

evidence indicating that Mrp1 provides protection in CM and CF in the face of
DOX cytotoxicity.
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A

B

Figure 3.1. Identification of neonatal mouse cardiomyocytes (CM) and
neonatal

mouse

cardiac

fibroblasts

(CF).

(A)

Representative

immunofluorescent staining for α-actinin (red fluorescence) in CM (A, left). A,
right: negative control (use of mouse IgG instead of α-actinin antibody) in CF
culture.

(B) Representative immunofluorescent staining for anti-vimentin (red

fluorescence) in CF (B, left). B, right:

negative control (use mouse IgG instead

of anti-vimentin antibody) in CF culture. DAPI (4',6-diamidino-2-phenylindole)
staining was used to identify individual nuclei.
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A

B

C

D

Figure 3.2. DOX increased Mrp1 expression in CM and CF culture.
Quantitative analysis of Mrp1 mRNA expression (detected by Real - Time PCR)
in CM (A) and CF (B) 24 h after treatment with saline or varying concentrations of
DOX. Quantitative analysis of Mrp1 protein expression (detected by Western
blot) in CM (C) and CF (D) 24 h after treatment with saline or DOX. The blots are
representative of one of 3 independent experiments. Each bar represents the
mean + SD. (*, p < 0.05 by Dunnett's post-test after one-way ANOVA)
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A

B

Figure 3.3. Effects of DOX on cell viability in WT and Mrp1-/- cells. CM (A)
and CF (B) were cultured on a 96-well plate for 48 h before treatment with
varying concentrations of DOX for 3 h, followed by incubation in fresh medium.
Tetrazolium reduction was measured 48 h after DOX removal.
represents the mean ± SD from 3 independent experiments.

Each point

Expression of

Mrp1 was detected by Western blot in WT and Mrp1-/- CM (A) and CF (B) (*, p <
0.05 by Student’s t-test)
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A

B

Figure 3.4. Effects of DOX on cell apoptosis in WT and Mrp1-/- cells.

The

greater increase of cleaved PARP, and cleaved caspase-3 in CM (A) and CF (B)
derived from Mrp1-/- mice was detected by Western blot 24 h after DOX removal.
The blots are representative of one of 3 independent experiments.

Each bar

represents the mean ± SD. (*, p < 0.05 by Newman-Keuls multiple comparison
test after one-way ANOVA)
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A

B

Figure 3.5 A and B. Effects of DOX on DNA damage in WT and Mrp1-/- CM.
The greater increase of γH2A.X in CM derived from Mrp1-/- mice was detected
by Western blot 0 h, 3 h, 6 h, 12 h (A) and 24 h (B) after DOX removal. The blots
are representative of one of 3 independent experiments. Each bar represents
the mean ± SD. (*, p < 0.05 by Newman-Keuls multiple comparison test after
one-way ANOVA).
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C

D

Figure 3.5 C and D. Effects of DOX on DNA damage in WT and Mrp1-/- CF.
The greater increase of γH2A.X in CF derived from Mrp1-/- mice was detected by
Western blot 0 h, 3 h, 6 h, 12 h (C) and 24 h (D) after DOX removal. The blots
are representative of one of 3 independent experiments. Each bar represents
the mean ± SD. (*, p < 0.05 by Newman-Keuls multiple comparison test after
one-way ANOVA).
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Figure 3.6. Accumulation of DOX in WT and Mrp1-/- CM and CF. Cells were
treated with 30 µM DOX. Following 1 h of incubation, cells were washed three
times with PBS and incubated with fresh DMEM medium for the indicated times.
Finally, the cells were washed three times with PBS and incubated in acidified
(0.75 N HCl) isopropanol with 1% Triton X-100 and shaken for 30 min at room
temperature. The absorbance of the supernatant was read using a fluorescence
spectrofluorometer at wavelengths of Ex=470 nm and Em=590 nm. The value of
DOX accumulation within the cells was calculated according to the standard
curve. Each point represents the mean ± SD (n = 3).

Copyright © Wei Zhang 2015
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Chapter Four

Mechanisms of Mrp1’s cardiac protective function

Overview of Study
The data presented in Chapter 2 demonstrated that the loss of Mrp1
potentiates DOX-induced cardiac dysfunction in mice. Chapter 3 further revealed
the protective role of Mrp1 against DOX toxicity in two major cell components of
heart tissue: cardiomyocytes and cardiac fibroblasts. This chapter explores the
mechanisms involved in Mrp1’s protection against DOX toxicity.
In the present study, GSH and GSSG levels were measured to evaluate the
redox status in chronic DOX-treated mouse heart and CM/CF culture.
Expression of GSH synthesis enzymes was measured to examine the possible
mechanisms responsible for the changes in GSH levels. The GS-HNE levels in
mouse heart were also assessed by LC/MS/MS. The protein oxidative damage
in CM and CF culture were also measured, including protein carbonyl, HNEprotein adducts and 3 nitrotyrosine-protein adducts.

Multiple antioxidant

enzymes expression levels were also examined. The results showed that loss of
Mrp1 caused increased GSH and GSSG levels in untreated or saline treated
mouse heart and in CM/CF culture. Following 0.5 μM DOX treatment, Mrp1-/CM showed increased GSH (1.7±0.3-fold) and GSSG (1.8±0.2-fold) levels
relative to WT CM (p < 0.05), however the redox potential (Eh) of the GSH/GSSG
pool was not changed. Similar effects were observed in CF. The increased GSH
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pool after DOX treatment in Mrp1-/- cells is at least partially due to the increased
GSH synthesis since DOX increased mRNA and protein expression of the ratelimiting GSH synthesis enzymes glutamate-cysteine ligase catalytic (GCLc) and
glutamate-cysteine ligase regulatory subunits (GCLm) in Mrp1-/- but not WT cells.
DOX treatment increased GS-HNE levels in mouse heart, but without an obvious
difference between genotypes. Finally, expression of extracellular superoxide
dismutase (ECSOD/SOD3) was lower in Mrp1-/- CM vs. WT CM treated with
either saline (62±8% of WT) or DOX (43±12% of WT) (p < 0.05). Taken together,
these data clearly showed that Mrp1 affected the intracellular GSH and GSSG
levels in mouse heart tissue as well as in the CM and CF culture. In treatmentnaïve Mrp1-/- mouse heart and cells, the higher GSH level is likely due to the
loss of efflux mediated by Mrp1. But with DOX treatment, the further increase of
the GSH pool in Mrp1-/- CM and CF involves the activation of the Nfr2 pathway
and increased GSH synthesis. Unlike our hypothesis, loss of Mrp1 does not
affect the intracellular level of GS-HNE in DOX treated mouse heart, implying
that complex compensatory effects occur.

Introduction
GSH is the most abundant cellular non-protein thiol and is a critical factor
responsible for the maintenance of cellular redox balance under oxidative stress.
In the presence of ROS, GSH is rapidly oxidized to GSSG, resulting in a
decreased intracellular GSH/GSSG ratio, an indicator of oxidative stress.
Maintenance of GSH homeostasis plays a vital role in a multitude of cellular

88

processes, including drug and free radical detoxification, cell differentiation,
proliferation and apoptosis (Jones, 2008). Mrp1-/- mice have increased basal
levels of GSH due to the decreased Mrp1-mediated efflux, while overexpression
of Mrp1 decreases intracellular levels of GSH (Cole et al., 1990; Rappa et al.,
1997). Our previous study showed that the treatment-naïve Mrp1-/- mouse heart
has a significantly higher GSH level compared to WT mice. In addition, Mrp1
also mediates the efflux of GSSG so that loss of Mrp1 could potentially disrupt
the balance of the GSH/GSSG redox couple, impairing a normal tissue’s ability to
protect itself against oxidative stress-induced injury.
HNE is an α, β-unsaturated aldehyde derived from peroxidation of ω-6
polyunsaturated fatty acids, and a toxic product of lipid peroxidation (Esterbauer
et al. 1991; Butterfield and Stadtman 1997).

It is partially detoxified by

conjugation with GSH, either spontaneously or through GSH-S-transferase (GST)
to form GS-HNE, which must be effluxed to alleviate intracellular toxicity (Volkel
et al., 2005).

Our laboratory had previously reported that mutant MRP1

Gly671Val impairs MRP1’s ability to efflux GS-HNE by more than 80%
(Jungsuwadee et al., 2012). Also, the HEK cells that overexpress this mutant
MRP1 (Gly671Val) are more sensitive to DOX toxicity relative to cells expressing
wild-type MRP1.

Furthermore, HNE adducted protein is increased in mouse

heart after DOX treatment and sarcolemmal membrane vesicles from Mrp1-/mouse are unable to transport GS-HNE, indicating that Mrp1 is the only ATP
dependent efflux transporter present in the mouse heart (Jungsuwadee et al.,
2006).
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Aerobic organisms possess antioxidant defense systems to protect cells
from the damage caused by ROS. Superoxide dismutase (SOD) and catalase
are two important antioxidant enzymes which remove •O 2- and H2O2, respectively
and maintain the normal redox status in cells. Thus, the regulations of these
genes at both expression and activity levels play pivotal roles in balancing the
concentration of ROS.

SOD converts two •O2- into one molecule of H2O2 and

one molecule of O2, while catalase further catalyzes the decomposition of H2O2
into H2O and O2.

In mammals, three distinct isoforms of SOD have been

identified

characterized:

and

copper-zinc

superoxide

dismutase

(Cu,ZnSOD/SOD1), manganese superoxide dismutase (MnSOD/SOD2) and
extracellular superoxide dismutase (ECSOD/SOD3).

Three forms of SOD

convert •O2- into H2O2, but have distinct protein structures, metal cofactor
requirements, and intracellular localizations (Miao and St Clair, 2009).
Cu,ZnSOD is localized mainly in cytoplasm and nucleus, while MnSOD resides in
the mitochondrial matrix.

The physiological role of MnSOD has been

demonstrated in that MnSOD knockout mice died shortly after birth with dilated
cardiomyopathy and neurodegeneration (Li et al., 1995; Lebovitz et al., 1996).
Further, overexpression of MnSOD in mice protects heart against DOX-induced
cardiotoxicity (Yen at el., 1996; Yen at el., 1999). ECSOD is a copper- and zinccontaining dismutase and it is the only isoform of SOD responsible for
scavenging •O2- in the extracellular environment.

It is a glycosylated

homotetrameric enzyme (155 kDa) that is secreted from cells to bind heparin
sulfate proteoglycans on the cell surface and in the extracellular matrix. There,
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ECSOD converts •O2- into less toxic H2O2. In addition, ECSOD plays a key role
in preserving the bioavailability of nitric oxide by protecting it against destruction
by •O2- and formation of highly toxic peroxynitrite.

Despite their effects on

maintaining the normal redox status, antioxidant enzymes are also regulated by
oxidative stress at both the expression level and activity level (Li and Singal,
2000; Franco et al., 1999).
GSH, GSSG and GS-HNE are substrates of Mrp1, and they are either
related to redox status regulation or are toxic oxidative stress products
themselves. Thus, we expected that Mrp1 plays an important role in oxidative
stress regulation. In this chapter, experiments were conducted to explore how
Mrp1 affects GSH, GSSG, and GS-HNE intracellular levels as well as expression
of other antioxidant enzymes.

Materials and methods
Measurement of GS-HNE in mouse heart by LC-MS/MS
Heart ventricle (50 mg tissue), prepared by removal of the atrium and
attached fat tissue and vessels, was homogenized in 400 μL of distilled water
followed by addition of 50 μL of 1 μM d3-GS-HNE. The chemical purity of d3-GSHNE was determined by LC-MS.

Proteins were precipitated from heart

homogenate by adding 1600 μL of ice-cold acetonitrile followed by vortexing for 5
min and centrifugation at 4000 rpm for 10 min. The supernatant was transferred
to a 4 mL glass vial and dried under N2. The dried samples were reconstituted in
100 μL of acetonitrile:H2O (50:50), vortexed and let stand at room temperature

91

for 10 min, and centrifuged at 15000 rpm for 5 min. The supernatants were then
transferred to autosampler vials. Analysis of GS-HNE was carried out using a
Shimadzu High performance Liquid Chromatograph coupled with an AB Sciex
4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer (MS)
operated in multiple reaction monitoring (MRM) mode.

The samples were

separated on a Machery-Nagel Nucleodur C8 Gravity column (2.0 mm×125 mm,
5 µm) by gradient elution with 0.05% formic acid in water (solvent A) and
acetonitrile: water (95:5) containing 0.05% formic acid (solvent B) according to
the following program: 100% solvent A for the first 1 min, then linear to 100%
solvent B over the next 3 min, and maintained at 100% B for the last 2 min. The
column was equilibrated back to the initial conditions within 3 min. The flow rate
was 0.5 mL/min with a column temperature of 30°C.

The sample injection

volume was 10 µL. The MS was operated in the positive electrospray ionization
mode with optimal ion source settings with a declustering potential of 71 V,
entrance potential of 10 V, collision energy of 21 V, collision cell exit potential of
8 V, curtain gas of 20 psi, ion spray voltage of 5500 V, ion source gas1/gas2 of
40 psi and temperature of 550°C. MRM transitions monitored were as follows:
464.2/308 and 464.2/446.

d3-GS-HNE was used as an internal standard for

quantitation of GS-HNE with the following MRM ion transitions: 467.2/308.1 and
467.2/449. Both pairs of fragments gave very similar quantitative results and
data presented in this dissertation are based on the fragments 464.2/446.
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Heart ventricle homogenate
The heart ventricle was prepared by removal of the atrium and attached fat
tissue and vessels, and then homogenized in 10 volumes of ice-cold buffer
consisting of 0.225 M mannitol, 0.075 M sucrose, 1 mM EGTA, and protease
inhibitors (1 mM phenylmethyl sulfonyl fluoride, 1 μg/mL leupeptin, 1μg/mL
aprotinin, and 1 μg/mL pepstatin). The protein concentrations of heart ventricle
homogenates were determined with the bicinchoninic acid (BCA) protein assay.

HPLC assay of GSH and GSSG
For animal study, heart ventricle homogenate prepared as above was used
for GSH derivatization and quantification of GSH and GSSG. For cell culture
study, CM (106 cells) or CF (3 X 105 cells) were plated and cultured on 6 well
plates overnight and treated with 0.5 µM or 1 µM DOX for 3 h, and 24 h later,
cells were scraped off and lysed with RIPA buffer. The cell lysate was used for
GSH derivatization and quantification of GSH and GSSG.

For GSH

measurement, the supernatant was added to redox quenching buffer (20 mM HCl,
5 mM diethylenetriaminepentaacetic acid, and 10 mM ascorbic acid) and then
mixed with monobromobimane (MBB; prepared in HPLC-grade acetonitrile)
derivatization buffer to yield final concentrations of 30 mM NaOH, 250 mM
diethylenetriaminepenta acetic acid, and 2.5 mM MBB (Senft et al, 2000).
Derivatization of GSH with MBB was carried out at 45°C for 15 min and the
reaction stopped by addition of 0.6 N HCl. GSSG was derivatized by the same
method following pretreatment of the heart homogenate with 0.5 mM N-
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ethylmaleimide to conjugate free GSH and reduction of GSSG to GSH by
addition of 5 mM dithiothreitol. The MBB-derivatized samples were centrifuged
and the supernatants assayed for thiol-bimane fluorescence by HPLC using a
linear gradient from 0-100% solvent B (50% methanol and 0.25% acetic acid in
water) in solvent A (10% methanol and 0.25% acetic acid in water) within 28 min
at a flow rate of 0.8 mL/min with fluorescence detection at Ex370/Em485, detected
with the Waters 2475 Multi λ fluorescence detector as described (Senft et al.,
2000).

Fluorescence intensities versus time of elution were quantified using

Waters Breeze chromatography software v.3.2 (Waters Corporation, Milford,
USA) and peak areas were integrated and converted to nmol equivalents
according to the GSH standard curve.
The redox potential (Eh) of the GSH/GSSG pool was determined in CM and
CF culture.

It was calculated using the estimated cellular GSH and GSSG

concentrations and the Nernst equation: Eh = Eo + (RT/nF) ln([GSSG] /[GSH]2).
To estimate cellular concentrations, 1 mg of cell protein was assumed to be
associated with 5 µl of cell volume (Mannery et al., 2010). R is the gas constant,
T is temperature, n is the number of electrons transferred, F is the faraday
constant, and Eo = - 264 mV at a pH of 7.4.

Immunoblot Assay
Immunoblot assays were conducted as described in Chapter 3. Antibodies
were obtained as follows: rabbit anti-GCLc pAb (ab80841), rabbit anti-GCLm pAb
(ab8144), and Rabbit anti-Nqo1 pAb(ab34173) from Abcam (Cambridge, MA),
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mouse anti-catalase mAb (sc-271803), rabbit anti-Cu,Zn superoxide dismutase
(Cu,ZnSOD) pAb ( sc-11407) from Santa Cruz Biotechnology (Santa Cruz, CA),
rabbit anti-Mn superoxide dismutase (MnSOD) pAb from Upstate (Lake Placid,
NY).

Rabbit anti-ECSOD pAb was a generous gift from Dr. Ladislav Dory,

University of North Texas.

Slot blot assay
CM and CF cell pellets were sonicated in a lysis buffer (0.32 Sucrose, 2mM
EDTA, 2mM EGTA; 20mM HEPES) containing the protease inhibitors leupeptin
(4 μg/mL), pepstatin (4 μg/mL), aprotinin (5 μg/mL), and PMSF (0.2 mM) with pH
7.4 (measured at room temperature). Small amounts of homogenates (3 uL)
were used to determine the total protein concentration by the BCA method
(Pierce, Rockford, IL). For protein carbonyl determination, samples were
derivatized with 2,4- dinitrophenylhydrazine (DNPH). For protein-bound HNE and
3-NT, 3 uL of the homogenized sample was mixed and diluted with an equal
volume of 12% SDS. Samples were further denatured with 10 μL of modified
Laemmli buffer (0.125 M Trizma base, 4% SDS, and 20% glycerol) for 20 min at
room temperature. Next, 250 ng of the derivatized protein was loaded in each
slot (48-well slot format Bio-Dot SF apparatus with nitrocellulose membranes,
pore size 0.45 μm, Bio-Rad, Hercules, CA, USA). The membranes were
incubated with primary antibodies anti-3-NT pAb (from Life Technologies,
Carlsbad, USA; dilution 1:2500), anti-protein-bound HNE pAb (from Alpha
Diagnostic International, San Antonio, TX, USA; dilution 1: 500) or polyclonal
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RbxDNP (from OxyBlot Protein Oxidation Detection Kit, Chemicon-Millipore,
Billerica, MA, USA, dilution1:200) and goat 1:7500 anti-rabbit IgG (Sigma–Aldrich)
antibody for the secondary detection. The antibody reaction was developed using
5-bromo-4-chloro-3-indolyl phosphate in conjunction with nitroblue tetrazolium.
The nitrocellulose membranes were dried overnight and scanned by photo
scanner (Epson Perfection V600, Long Beach, CA, USA), and slot-blot line
densities were quantified by the ImageQuant TL software package (GE
Healthcare Bio-Sciences, Piscataway, NJ, USA).

RNA extraction and real-time quantitative PCR (qRT-PCR)
Total RNA extraction, cDNA preparation and qRT-PCR were conducted as
described in Chapter 2. The sequence of primers and Universal ProbeLibrary
probe for specific genes are shown in Table 4.1.

Statistical analysis
All data are expressed as the mean ± SD or mean ± SE for n = 3 to 6 per group,
as detailed in the Figure Legends. In studies comparing two groups, statistical
analysis was performed with the Student’s t-test. In studies comparing multiple
groups to the same control group, statistical analysis was performed with oneway ANOVA followed by Dunnett's post-test. In studies comparing more than
two groups, statistical analysis was performed with one-way ANOVA followed by
Newman-Keuls multiple comparison test.
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Results
DOX treatment increases GS-HNE level in mouse heart tissue
DOX initiates ROS and causes lipid peroxidation, while HNE is the one of the
major toxic lipid metabolites. The highly electrophilic HNE reacts rapidly with
nucleophiles, particularly GSH, to form GS-HNE, which is a substrate of Mrp1.
Here, the retention of GS-HNE was characterized in WT and Mrp1-/- mouse
heart tissue following chronic DOX treatment (2 mg/kg). As shown in Figure 4.1,
chronic DOX treatment increased GS-HNE levels in WT and Mrp1-/- mouse heart
at 48 h (Figure 4.1A) and 2 weeks (Figure 4.1B) after the last DOX treatment.
The increase was statistically significant only at 2 weeks, but not 48 h after the
last DOX treatment. However, in contrast to our expectations, there was no
significant difference in GS-HNE levels between genotypes.

GSH and GSSG levels in mouse heart tissue
As GSH and GSSG are known substrates for Mrp1, we investigated whether
loss of Mrp1 would alter GSH and GSSG levels in the cell, and therefore disrupt
the balance of the GSH/GSSG redox couple. In the in vivo study, GSH and
GSSG level were examined in mouse heart 48 h and 2 weeks after the last dose
of DOX in the chronic treatment. DOX treatment significantly decreased both
GSH and the GSH/GSSG ratio at 48 h, indicating DOX-induced oxidative stress
(Figure 4.2A). GSH and GSH/GSSG returned to control levels two weeks later,
at the end of the recovery period (Figure 4.2B).

Although there was no

significant difference in the GSH/GSSG ratio between WT and Mrp1-/- mice at
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either time point, it is interesting to note the significantly higher basal (saline
treatment) levels of GSH and GSSG in Mrp1-/- compared to WT mouse heart.
GSSG levels were also significantly increased in Mrp1-/- vs WT mice following
DOX treatment at both time points.

This observation is consistent with the

function of Mrp1 to efflux GSH and GSSG.

GSH and GSSG measurement in CM and CF
The intracellular GSH and GSSG levels in CM and CF culture were also
assessed.

Consistent with our findings in treatment-naïve and saline-treated

mice, untreated CM and CF derived from Mrp1-/- mice had significantly higher
GSH and GSSG levels compared to WT cells (Figure 4.3).

However, no

difference in the GSH/GSSG ratio was observed between genotypes.

This

question was further investigated in DOX treated cells. In preliminary studies,
the time course of the changes in GSH and GSSG in cells following DOX
treatment was examined. CM were treated with saline or DOX, and intracellular
GSH and GSSG examined at various times over 24 h. As shown in Figure 4.4,
the GSH level decreased and the GSSG level increased rapidly in both WT and
Mrp1-/- CM within 15 min after addition of DOX. Over the next 24 h, GSH and
GSSG levels gradually returned to basal levels in WT CM. However, GSH and
GSSG levels continuously increased and remained at a higher level in Mrp1-/cells. Subsequent studies characterized GSH and GSSG levels at the 15 min,
30 min and 24 h time points after treatment with DOX. At 15 min and 30 min
after DOX treatment, GSH levels decreased and GSSG levels increased in both
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WT and Mrp1-/- CMs.

Thus, the GSH/GSSG ratio (Figure 4.5A) of the

GSH/GSSG pool decreased and the redox potential (Eh) (Table 4.2) became
less negative in DOX treated cells. However, GSH and GSSG levels in Mrp1-/cells were significantly increased 24 h after DOX treatment, but were not different
in WT cells (Figure 4.6A). As a consequence, the GSH/GSSG ratio and the
redox potential (Eh) of the GSH/GSSG pool did not change in either genotype
with either treatment (Table 4.3). Similar effects were observed in CF cultures
(Figure 4.5B and 4.6B).

Expression of GSH biosynthesis enzymes
The increase in GSH levels after DOX treatment in Mrp1-/- cells could be due
to decreased GSH efflux, increased GSH biosynthesis or increased recycling
from GSSG. Thus, the mRNA and protein expression levels of GSH biosynthesis
enzymes and GSH reductase (GR) were examined. As shown in Figure 4.7A,
DOX treatment significantly increased both mRNA and protein expression of
GCLc, GCLm, and glutathione synthetase (GSS) at 24 h in Mrp1-/- CM, but had
no effects in WT CM. DOX treatment had no effect on GR protein expression in
either genotype (data not shown). Similar results were observed in CF (Figure
4.7B). These data indicate that the higher level of GSH in DOX treated Mrp1-/cells could be at least partly due to the increased expression of GSH
biosynthesis enzymes, and a subsequent higher rate of GSH synthesis.
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Protein expression of antioxidant enzymes
The expression of important antioxidant enzymes were exmined, and showed
that in both CM and CF, DOX slightly increased protein expression of catalase,
Cu,ZnSOD and MnSOD in both genotypes, but these changes were not
statistically significant (Figure 4.8). However, the mRNA and protein expression
of SOD3 was decreased in Mrp1-/- CM compared to WT CM after saline
treatment (64 ± 2% of WT mRNA level, p < 0.05, 62 ± 8% of WT protein level, p
< 0.05) (Figure 4.9A). DOX treatment significantly decreased the expression of
SOD3 in both WT and Mrp1-/- CM, such that SOD3 expression was still lower in
Mrp1-/- CM (46 ± 5% of WT mRNA level, p < 0.05, 43 ± 12 % of WT protein level,
p < 0.05). Interestingly, this difference in SOD3 between genotypes was not
observed in CF (Figure 4.9B). The mRNA expression of glutathione peroxidase
(Gpx), glutathione S-transferase (GST) and NAD(P)H dehydrogenase, quinone 1
(NQO1), heme oxygenase 1 (HO-1) were also detected and DOX increased
expression of GPx1, GPx3, GSTM1 and GSTM2 in both WT and Mrp1-/- CM and
CF, but there was no difference between genotypes (Figure 4.10). However,
mRNA and protein expression of Nqo1 was higher and HO-1 mRNA expression
was significantly elevated in Mrp1-/- vs WT CM and CF after DOX treatment
(Figure 4.11).

Protein oxidative damage in DOX treated CM and CF
Protein oxidative damages in CM and CF were also detected culture including
HNE-protein adducts, 3 nitrotyrosine-protein adducts and protein carbonyl levels.
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Although we expected that the oxidative stress induced by DOX would increase
these measures of protein oxidative damages, within 30 min after the DOX
treatment, these protein oxidative damage markers just slightly increased in DOX
treated cell culture in both genotype.

However, these increases were not

statistically significant. There was no obvious difference observed between WT
and Mrp1-/- cells (Figure 4.12).

Similar results were obtained in samples

collected 24 h after DOX treatment.

Discussion
Changes in HNE formation and GSH/GSSG homeostasis are two important
consequences of oxidative stress.

Since GS-HNE, GSH and GSSG are all

substrates of Mrp1, we hypothesized that loss of Mrp1 would change the efflux of
these molecules and potentially cause abnormal cellular responses to oxidative
stress. This chapter explores the effects of Mrp1 on redox status in mouse heart
as well as in CM and CF culture. Measurements conducted included levels of
intracellular GS-HNE, GSH and GSSG as well as expression of antioxidant
enzymes and protein oxidative damage.
An increase in HNE and HNE adducted protein are detected in heart tissues
as early as 3 hr following DOX administration (Luo et al., 1997; Liu and Tan,
2003; Chaiswing et al., 2004). Further, sarcolemmal membrane vesicles from
Mrp1-/- mouse are unable to transport GS-HNE, indicating that Mrp1 is the only
ATP dependent efflux transporter of GS-HNE in the mouse heart (Jungsuwadee
et al., 2006; Jungsuwadee et al., 2012). Here, chronic DOX treatment increased
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GS-HNE in the mouse heart, indicating that DOX-induced oxidative stress. It
was anticipated that the loss of Mrp1 would eliminate the efflux of GS-HNE and
cause its intracellular accumulation. However, there was no significant difference
in the GS-HNE concentration between WT and Mrp1-/- mice heart. These data
imply a complex adaptation in Mrp1-/- mice. To protect macromolecules from
modification or adduction by HNE, mammalian cells metabolize HNE rapidly. In
addition to conjugation with GSH to yield GS-HNE, HNE metabolism includes
reduction to the corresponding alcohol, 1,4-dihydroxy-2-nonene (DHN) or
oxidation to the corresponding acid, 4-hydroxy-2-nonenoic acid (HNA) (Alary et
al., 2003; Volkel et al, 2005). The loss of GS-HNE efflux may saturate these
metabolic pathways, but can also lead to metabolism of GS-HNE via an NADHdependent alcohol dehydrogenase (ADH)-catalyzed reduction to GS-DHN and/or
aldehyde dehydrogenase-catalyzed oxidation to GS-HNA.

The biological

activities of these GSH conjugates are not yet well characterized nor has their
cellular efflux by Mrp1 been described (Dalleau et al., 2013; Frohnert and
Bernlohr, 2014). We did not measure these additional HNE metabolic products,
thus we cannot conclude whether loss of Mrp1 alters HNE metabolism in mouse
heart.
One of the mechanisms whereby cells maintain their redox status is by
maintaining the GSH/GSSG ratio.

Since Mrp1 can transport both GSH and

GSSG, we hypothesized that loss of Mrp1 would disrupt the GSH/GSSG balance.
In our chronic treatment mouse model, GSH and the GSH/GSSG ratio decreased
at 48 h after the last dose of DOX.

In CM and CF culture, GSH and the
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GSH/GSSG ratio decreased very quickly, within 15 min of DOX addition.
Although as an indicator of intracellular oxidative stress, the GSH/GSSG ratio
was similar between WT and Mrp1-/- mice heart and cell culture, the GSH and
GSSH levels were always higher in Mrp1-/- mice hearts and Mrp1-/- cells
compared to WT. This is consistent with our previous finding that treatmentnaïve Mrp1-/- mice heart had significantly higher GSH compared to WT mice, as
well as to other group’s finding regarding the effects of Mrp1 on the intracellular
GSH level.
A major determinant of cellular GSH homeostasis is GCL, which catalyzes the
first and rate-limiting step in de novo synthesis of GSH from glutamate and
cysteine.

Its activity is controlled by a complex regulation at several levels,

including transcriptional activation by oxidative stress, reversible formation of a
disulfide bond between its two subunits (GCLc and GCLm), and the feedback
inhibition by GSH (Richman et al., 1975; Huang et al., 1993; Fraser et al., 2003;
Franklin et al., 2009).

in this study, even in the absence of a significant

difference in GCLc and GCLm expression, the treatment-naïve Mrp1-/- mice
heart and saline treated Mrp1-/- cells exhibited higher GSH compared to WT
mice heart and cells. These data indicate the important role of Mrp1-mediated
efflux in intracellular GSH regulation. Although it is known that GCL activity is
feedback-inhibited by GSH, we did not measure GCL activity so do not know the
extent of feedback inhibition in treatment-naïve Mrp1-/- cells. We also found that
DOX increased concentrations of GSH and GSSG in Mrp1-/- cells but not WT
cells; however, the redox potential (Eh) of the GSH/GSSG pool was similar
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between genotypes.

To test whether this increased GSH pool was due to

increased GSH synthesis, the expression of GSH synthesis enzymes GCLc,
GCLm and GSS were examined.

After DOX treatment, Mrp1-/- cells have

significantly higher expression of GCLc and GCLm at both mRNA and protein
levels compared to WT cells. The expression of GCLc, GCLm and GSS are all
known to respond to oxidative stress and all three genes are upregulated by Nrf2
pathway activation at the transcription level.

In this study, the expression of

NQO1 and HO-1, two typical downstream genes of the Nrf2 pathway, were
significantly higher in DOX treated Mrp1-/- cells vs WT cells.

These data

indicated that the greater Nrf2 pathway activation caused increased expression
of GCLc and GCLm in Mrp1-/- cells. We did not measure GCL activity in DOX
treated cells, and we do not know whether enzyme activity was inhibited by the
high level of GSH in Mrp1-/- cells. We speculate that such feedback inhibition
occurred, but was not sufficient to decrease the overall GSH synthesis rate
because of the enhanced expression of the GCL enzymes which were
upregulated at the transcription level.

Thus, the feedback inhibition of GCL

activity by GSH is not the major determinant of GSH levels in DOX treated Mrp1/- cells. Taken together, these results suggest that despite comparable Eh for
GSH/GSSG in WT and Mrp-/- cells, the oxidative stress Mrp1-/- cells suffer
stimulates the Nrf2 signaling pathway, causing the upregulation of the GSH
synthesis enzymes at the transcriptional level.

Importantly, the higher

intracellular GSH level and the increase of GCLc and GCLm expression still
cannot protect the Mrp1-/- cell from DOX-induced cytotoxicity.

104

Recently, an emerging concept, reductive stress, may provide some clue
regarding why the higher GSH level could not rescue Mrp1-/- cells from DOX
toxicity (Narasimhan et al., 2015). There are increasing examples of excessive
amounts of reducing equivalents, in the forms of NAD(P)H and/or GSH, resulting
in cellular dysfunction and cardiac disease (Narasimhan et al., 2015, Brewer et
al., 2012).

Zhang et al. (2010) reported that overexpression of heat shock

protein HSP2 leads to an increased ratio of GSH/GSSG, and a decrease of ROS,
yet resulted in cardiomyopathy. The human mutant αB-crystallin overexpression
mouse model characterized by Rajasekaran et al. (2007; 2011) shows sustained
activation of the Nrf2 signaling pathway, increases in GSH and the GSH/GSSG
ratio, and hypertrophic cardiomyopathy.

Involvement of reductive stress is

further demonstrated by the fact that quenching of reducing power rescued the
mice from heart failure (Rajasekaran et al., 2007; Rajasekaran et al., 2011). The
more recent study indicates that GSH-induced reductive stress is causally linked
to mitochondrial oxidation and cytotoxicity, with the mechanism not fully
understood (Zhang et al., 2012). In our study, compared to WT cells, Mrp1-/cells had significantly higher GSH and GSSG after saline treatment and even
higher after DOX treatment. This is a little surprising since we expected the
change of GSH and GSSG level elicited by DOX would return to pretreatment
levels after the appropriate antioxidant cellular response had taken effect.
However, we saw sustained activation of Nrf2 signaling and upregulation of GSH
synthesis enzymes in DOX treated Mrp1-/- cells. We postulate that in DOXtreated Mrp1-/- cells, the normal redox signaling activation and compensatory
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responsiveness are disrupted and lead to cytotoxic consequences. However, we
did not observe any structural or functional tissue injury in saline treated Mrp1-/mice heart (Deng et al., submitted). Thus, it is unlikely that reductive stress is a
major contributor to the observed cardiac injury after DOX. Other measurements,
including NADPH/NADP, a battery of antioxidant enzymes and oxidative stress
markers, need to be assessed before making any conclusions regarding the role
of reductive stress in Mrp1-/- mice heart.
In this study, we did not measure the extracellular GSH concentration, which
may serve to protect the interstitium from oxidants. If the loss of Mrp1 impairs
GSH efflux, loss of extracellular GSH may also accelerate oxidative damage in
the extracellular environment. In addition, the extracellular GSH can be broken
down in the extracellular space by γGT and dipeptidase, thus producing cysteine.
The lower extracellular GSH concentration could affect the cysteine/cystine
balance, which is also critical for maintaining extracellular redox status (Levonen
et al., 2004).

For example, extracellular GSH has been shown to offer

neuroprotection against methyl mercury toxicity in a manner dependent on
MRP1-mediated efflux (Rush et al. 2012). To test the importance of extracellular
GSH in CM and CF culture, exogenous non-cell penetrable GSH was added in
the medium and compared the cell survival following DOX treatment.

The

exogenous GSH reduced the cell death in WT and Mrp1-/- cells, with 10 mM
GSH eliminating the difference of cell viability between WT and Mrp1-/- cells
(Figure 4.10). This means that the lower GSH in the extracellular environment
could contribute to the DOX sensitivity in Mrp1-/- cells.
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Furthermore, the significance of GSSG, which is also transported by MRP1,
cannot be overlooked, given its cytotoxicity. The increased intracellular GSSG
concentration by microinjection or inhibition of the efflux through Mrp1 has been
shown to cause glutathionylation of cysteine-containing proteins, resulting in
damaged protein function, finally causing cell death (Park et al., 2009). Whether
this could happen in Mrp1-/- mouse heart is not known. All these possibilities
need to be confirmed by more studies.
Numerous studies have shown that GSH depletion is a common feature of
apoptosis induced by a variety of stress. GSH depletion has been associated
with apoptosis either by predisposing cells to apoptosis or by modulating
mitochondrial membrane potential and subsequent activation of caspases
(Armstrong et al., 2002). GSH depletion could be mediated through its oxidation
to GSSG by ROS, the efflux through GSH transporters or the loss of membrane
integrity (Circu et al., 2008; Franco et.al, 2007; Ghibelli et al., 1998; Hammond et
al., 2004).

Several studies have shown that prevention of GSH efflux could

attenuate or prevent apoptosis (Ghibelli et al., 1998; He et al., 2003; Circu et al.,
2009). However, conflicting results exist regarding the identity of the specific
transporter involved in GSH depletion. Several studies have suggested a role for
MRP1 in GSH depletion (Mueller et al., 2005; Hammond et al., 2007; Laberge et
al., 2007; Sreekumar et al., 2012). In contrast to those studies, other groups
demonstrated that inhibition of MRP1-mediated transport accelerates apoptosis
and GSH loss (Franco et al., 2007; Franco et al., 2014). The discrepancy among
these studies could be due to differences in cell types, cell culture conditions,
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levels of MRP1 expression, duration of the stress, the stimulus used to induce
apoptosis and GSH levels maintained during experimentation among various
studies. In our experiment, in the absence of Mrp1-mediated GSH efflux, the
Mrp1-/- cells were still more sensitive to DOX toxicity demonstrated as less cell
survival and more apoptosis compared to WT cells. Thus, GSH efflux mediated
by Mrp1 is not essential and not the major determinant of DOX-induced
apoptosis in CM and CF.
Another very important finding is that there was less ECSOD/SOD3
expression in Mrp1-/- CM compared to WT CM with either saline or DOX
treatment. Among the three SOD isoforms (Cu,ZnSOD, MnSOD2 and ECSOD),
ECSOD is the sole enzyme that is located in the extracellular matrix. It catalyzes
the dismutation of •O2- to H2O2 and O2, and maintains relatively low levels of O2•in the extracellular environment. Overexpression of ECSOD in heart tissue or
ECSOD administration in animal models has been shown to attenuate oxidative
stress and to mitigate tissue dysfunction in cardiovascular disease mimetics (Li et
al., 2001; Li et al., 1998; Wahlund et al., 1992).

Cardiac-speciﬁc ECSOD

overexpression attenuates ROS levels and increases NO bioavailability in
response to ischemia/reperfusion, thus protecting against reperfusion injury
(Obal et al., 2012). In contrast, lack of ECSOD leads to increases in myocardial
apoptosis and significantly more left ventricle fibrosis in mice treated with DOX
(Kliment et al, 2009). These data suggest that the lower ECSOD expression in
Mrp1-/- CM contributes to the greater sensitivity of CM to DOX. However, the
mechanism by which loss of Mrp1 decreases ECSOD expression remains
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unclear. An earlier study reported that treatment of two fibroblast lines with a
wide concentration range of oxidizing agents uniformly, dose-dependently and
continuously reduced ECSOD expression in a manner coordinated by cytokines,
rather than as a response of individual cells to oxidants (Strålin and Marklund,
1994). It is thus possible that the loss of Mrp1 places the cells under oxidative
stress, which in turn changes the cytokine regulation, and finally impairs the
expression of ECSOD. In addition, Reddy et al. (2007) reported that type II
alveolar epithelial cells derived from Nrf2-/- mice show significantly higher SOD3
mRNA expression compared to WT cells, while GSH supplementation in Nrf2-/cells decreases the SOD3 expression down to the level of WT cells. These data
are consistent with the Nrf2 activation, higher GSH level and lower SOD3
expression observed in Mrp1-/- CM. However, to further test whether oxidative
stress, Nrf2 activation or the high level of GSH caused the lower expression of
SOD3 in Mrp1-/- CM, we need to treat the CM with other oxidizing agents to see
if they cause similar effects as DOX, or we could deplete the GSH in CM culture
to see if it removes the difference of SOD3 expression between genotypes.
Taken together, loss of Mrp1 lead to lower expression of SOD3 and it may
contribute to the sensitivity of Mrp1-/- CM to DOX toxicity.
It is worth noting that the difference in SOD3 expression between genotypes
was only found in CM but not CF. It indicates that distinct regulation of SOD3
gene exist in these two cell types.

The different response of SOD3 gene

expression to DOX treatment in CM and CF are further studied and discussed in
the next chapter (Chapter 5).

However it is still largely unknown why loss of
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Mrp1 only deceases SOD3 expression in CM but not CF, how these ECSOD
produced by these two cell types coordinate with each other and how these
ECSOD proteins from different sources contribute to the DOX-induced
pathological changes in the heart. Studies focusing on these questions will be
very helpful to identify the function of SOD3 in specific cell components of heart.
In summary, the key findings of this study are that loss of Mrp1 caused an
increase of intracellular GSH and GSSG in both mouse heart and CM/CF culture.
Following DOX treatment, the increased GSH pool in Mrp1-/- CM and CF is due
to the loss of Mrp1-mediated efflux as well as the increased GSH synthesis. This
study shows that retention of intracellular GSH does not inhibit further GSH
synthesis in Mrp1-/- cells, thus providing important information regarding the
dynamics of Mrp1 in regulating cellular GSH levels. Since the role of GSH in
maintaining redox status is well understood, these data highlight the potential
role of Mrp1 in oxidative stress regulation. In addition, the effects of Mrp1 on
extracellular antioxidant defense systems, such as the extracellular GSH pool
and ECSOD, open a new field of study of Mrp1’s function that merits further
investigation.
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Figure 4.1. Concentration of GS-HNE in heart tissue. Mice were treated with
protocol B (2 mg/kg DOX each time, twice a week for 5 weeks), and GS-HNE
concentration in heart was measured by LC-MS/MS 48 h (A) or 2 weeks (B) after
the last dose of saline or DOX. Each bar represents the mean ± SE. (n = 5 for
saline treated group; n = 6 for DOX treated group. *, p < 0.05 DOX vs. saline of
the same genotype by Newman-Keuls multiple comparison test after one-way
ANOVA.)
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A

B

Figure 4.2. Assessment of GSH, GSSG and the GSH/GSSG ratio in mouse
heart. Mice were treated with protocol B (2 mg/kg DOX each time, twice a week
for 5 weeks), and GSH and GSSG concentrations measured by HPLC at 48 h (A)
or 2 weeks (B) after the last dose of DOX. Each bar represents the mean ± SE
(n = 6, *, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 vs.
respective WT mice by Newman-Keuls multiple comparison test after one-way
ANOVA).
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A

B

Figure 4.3. Concentration of GSH and GSSG, and the GSH/GSSG ratio in
untreated CM (A) and CF (B). GSH and GSSG were measured by HPLC.
Significantly higher basal levels of GSH and GSSG were observed in Mrp1-/cells compared to WT cells so that there was no difference in GSH/GSSG ratio
between genotypes. Each bar represents the mean ± SD (n = 3, * p < 0.01 by
Welch’s t- test)
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A

B

Figure 4.4. Dynamic changes of GSH, GSSG level, and the GSH/GSSG ratio
in CM and CF. CM (A) and CF (B) were treated with saline or DOX (0.5 µM in
CM and 1 µM in CF) for 3 h, then the saline or DOX containing medium was
removed and cells were incubated in fresh medium.

GSH and GSSG were

measured by HPLC at the indicated times after the addition of DOX.
represent results from one preparation of cells.
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Figure 4.5. Concentration of GSH and GSSG, and the GSH/GSSG ratio at 15
min and 30 min after DOX treatment in CM and CF. CM (A) and CF (B) were
treated with saline or DOX (0.5 µM in CM and 1 µM in CF). Fifteen min or thirty
min later, cell were harvested and GSH and GSSG were measured by HPLC.
Each bar represents the mean ± SD (n = 3; *, p < 0.05 DOX vs. 0 min of the
same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls
multiple comparison test after one-way ANOVA)
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A

B

Figure 4.6. Concentration of GSH and GSSG, and the GSH/GSSG ratio at 24
h after saline or DOX treatment in CM and CF. CM (A) and CF (B) were
treated with saline or DOX (0.5 µM in CM and 1 µM in CF) for 3 h, then the saline
or DOX containing medium was removed and cells were incubated in fresh
medium for another 24 h, at which time GSH and GSSG were measured by
HPLC. Each bar represents the mean ± SD (n = 3; *, p < 0.05 DOX vs. saline of
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by NewmanKeuls multiple comparison test after one-way ANOVA)
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A

Figure 4.7A. Quantitative analysis of GCLc, GCLm, and GSS expression in
CM. CM were treated with saline or 0.5 µM DOX for 3 h, then the saline or DOX
containing medium removed and cells incubated in fresh medium for another 24
h. The blots are representative of one of 3 independent experiments. Each bar
represents the mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #,
p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls multiple comparison
test after one-way ANOVA. GCLc (glutamate-cysteine ligase, catalytic subunit),
GCLm (glutamate--cysteine ligase, regulatory subunit), and GSS (glutathione
synthetase).
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B

Figure 4.7B Quantitative analysis of GCLc, GCLm, and GSS expression in
CF. CF were treated with saline or 1 µM DOX for 3 h, then the saline or DOX
containing medium removed and cells incubated in fresh medium for another 24
h. The blots are representative of one of 3 independent experiments. Each bar
represents the mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #,
p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls multiple comparison
test after one-way ANOVA. GCLc, glutamate-cysteine ligase, catalytic subunit;
GCLm, glutamate--cysteine

ligase, regulatory subunit;

synthetase.
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GSS, glutathione

A

Figure 4.8A. Quantitative analysis of antioxidant enzymes expression in CM.
CM were treated with saline or 0.5 µM and 1 µM DOX for 3 h, the saline or DOX
containing medium removed and cells incubated in fresh medium for another 24
h.

Protein expression was detected by Western blot.

The blots are

representative of one of 3 independent experiments. Each bar represents the
mean ± SD.
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B

Figure 4.8B. Quantitative analysis of antioxidant enzymes expression in CF.
CF were treated with saline or 1 µM and 3 µM DOX for 3 h, the saline or DOX
containing medium removed and cells incubated in fresh medium for another 24
h.

Protein expression was detected by Western blot.

The blots are

representative of one of 3 independent experiments. Each bar represents the
mean ± SD.
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A

B

Figure 4.9. Quantitative analysis ECSOD expression in CM and CF. CM (A)
and CF (B) were treated with saline or DOX (0.5 µM in CM and 1 µM in CF) for 3
h, the saline or DOX containing medium removed and cells incubated in fresh
medium for another 24 h. mRNA expression was detected by Real-Time PCR
and protein expression was detected by Western blot.

The blots are

representative of one of 3 independent experiments. Each bar represents the
mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1/- vs. respective WT cells by Newman-Keuls multiple comparison test after oneway ANOVA)
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A

Figure 4.10A. Quantitative analysis of GPx1, GPx3, GSTM1 and GSTM2
mRNA expression in CM. CM were treated with saline or 0.5 µM DOX for 3 h,
then the saline (SAL) or DOX containing medium removed and cells incubated in
fresh medium for another 24 h. mRNA expression was detected by Real - Time
PCR. Each bar represents the mean + SD. (n = 3; *, p < 0.05 DOX vs. saline of
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by NewmanKeuls multiple comparison test after One-way ANOVA) GPx, glutathione
peroxidase; GST, glutathione S-transferase;
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B

Figure 4.10B. Quantitative analysis of GPx1, GPx3. GSTM1 and GSTM2
mRNA expression in CF. CF were treated with saline or 1 µM DOX for 3 h,
then the saline (SAL) or DOX containing medium removed and cells incubated in
fresh medium for another 24 h. mRNA expression was detected by Real - Time
PCR. Each bar represents the mean + SD. (n = 3; *, p < 0.05 DOX vs. saline of
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by NewmanKeuls multiple comparison test after One-way ANOVA) GPx, glutathione
peroxidase; GST, glutathione S-transferase;

123

A

B

C

D

Figure 4.11. Quantitative analysis of Nqo1 and HO-1 mRNA and protein
expression in CM and CF. CM (A and C) and CF (B and D) were treated with
saline or DOX (0.5 µM in CM and 1 µM in CF) for 3 h, the saline (SAL) or DOX
containing medium removed and cells incubated in fresh medium for another 24
h. mRNA expression was detected by Real-Time PCR and protein expression
was detected by Western blot.

The blots are representative of one of 3

independent experiments. Each bar represents the mean ± SD. (n = 3; *, p <
0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT
cells by Newman-Keuls multiple comparison test after One-way ANOVA)
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A

Figure 4.12A. Protein oxidative damage in CM. CM were treated with saline
or 1 or 5 µM DOX for 30 min. Then, HNE-protein adducts, 3-nitrotyrosine-protein
adducts and protein carbonyl levels were assessed by slot-blot assay. NT, 3nitrotyrosine-protein adducts; PC, protein carbonyl.
mean + SE. (n = 3)
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Each bar represents the

B

Figure 4.12B. Protein oxidative damage in CF. CF were treated with saline or
2 or 5 µM DOX for 30 min. Then, HNE-protein adducts, 3-nitrotyrosine-protein
adducts and protein carbonyl levels were assessed by slot-blot assay. NT, 3
nitrotyrosine-protein adducts; PC, protein carbonyl.
mean + SE. (n = 3)
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Each bar represents the

B

A

Figure 4.13. Exogenous GSH rescued Mrp1-/- CM and CF. CM (A) and CF (B)
were cultured on a 96-well plate for 48 h before treatment with saline or DOX for
3 h. Tetrazolium reduction was measured 48 h after DOX removal.

Varying

concentrations of GSH were added to the medium during DOX treatment and
after removal of DOX. Only addition of 10 mM GSH eliminated the difference in
cell viability between WT and Mrp1-/- cells. Each bar represents the mean ± SD.
(n = 6, *, p < 0.05 by Newman-Keuls multiple comparison test after One-way
ANOVA)
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Table 4.1. Primers and Universal ProbeLibrary probes used for qRT-PCR
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Genes

Forward primer (5׳-3)׳

Reverse primer (5׳-3)׳

Universal Probe Library probe

18S rRNA

gcaattattccccatgaacg

gggacttaatcaacgcaagc

#48

GPx1

tttcccgtgcaatcagttc

tcggacgtacttgagggaat

#2

GPx3

ggcttcccttccaaccaa

cccacctggtcgaacatact

#92

GSS

agatggctacatgcccagtc

gcacgagatctctctagcatca

#48

GSTM1

gcagctcatcatgctctgtta

tttctcagggatggtcttcaa

#106

GSTM2

agttggccatggtttgctac

agcttcatcttctcagggagac

#106

GCLc

ctgcacatctaccacgcagt

gaacatcgcctccattcagt

SYBR green

GCLm

tgactcacaatgacccgaaa

tcaatgtcagggatgctttct

#108

HO-1

aggctaagaccgccttcct

tgtgttcctctgtcagcatca

#17

NQO1

agcgttcggtattacgatcc

agtacaatcagggctcttctcg

#50

SOD3

ctcttgggagagcctgaca

gccagtagcaagccgtagaa

#102

GPx, glutathione peroxidase; GSS, glutathione synthetase; GST, glutathione S-transferase; HO-1: heme oxygenase 1;
NQO1, NAD(P)H dehydrogenase, quinone 1; GCLc, glutamate-cysteine ligase catalytic subunit; GCLm, glutamatecysteine ligase regulatory subunit; Mrp1, multidrug resistance-associated protein 1; SOD3, superoxide dismutase 3.
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Table 4.2: Redox potential (Eh) of the GSH/GSSG pool in CM and CF
(15 min and 30 min)

Cell

Mice

CM

WT
Mrp1-/WT
Mrp1-/-

CF

0 min
-237.7 ±2.3
-240.6±1.6
-236.5±1.3
-239.4 ±2.5

Eh of GSH/GSSG (mV)
Ave ± SD
Treatment
DOX 15 min
DOX 30 min
-231.4± 0.8 *
-232.8± 2.6 *
-234.8±2.3 *
233.0± 3.0 *
-230.0±5.4
230.5± 3.5
-235.4 ±2.2
234.9± 1.9

The redox potential (Eh) of the GSH/GSSG pool in CM and CF at 15min and 30
min after DOX treatment. CM and CF were treated with DOX (0.5 µM in CM and
1 µM in CF) for 0, 15 and 30 min. Eh is calculated by the Nernst equation, Eh =
Eo + (RT/nF) ln([GSSG] /[GSH]2). To estimate cellular concentrations, 1 mg of
cell protein was assumed to be associated with 5 µl of cell volume (Mannery et
al., 2010). R is the gas constant, T is temperature, n is the number of electrons
transferred, F is the faraday constant, and Eo = - 264 mV at a pH of 7.4. Data
are presented as mean ± SD (n = 3; *, p < 0.05 DOX vs. 0 min of the same
genotype by Dunnett's post-test after one-way ANOVA)
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Table 4.3: Redox potential (Eh) of the GSH/GSSG pool in CM and CF
(24 h)

Cell

Mice

CM

WT
Mrp1-/WT
Mrp1-/-

CF

Eh of GSH/GSSG (mV)
Ave ± SD
Treatment
saline
DOX
-234.6 ±1.6
-229.1± 7.0
-234.8 ±2.7
-236.5 ±1.2
-235.4 ±3.0
-235.0±2.1
-237.7 ±1.0
-237.2 ±4.5

The redox potential (Eh) of the GSH/GSSG pool in CM and CF after saline or
DOX treatment. CM and CF were treated with saline or DOX (0.5 µM in CM and
1 µM in CF) for 3 h, the saline or DOX containing medium removed and cells
incubated in fresh medium for another 24 h. Eh is calculated by the Nernst
equation, Eh = Eo + (RT/nF) ln([GSSG] /[GSH]2).

To estimate cellular

concentrations, 1 mg of cell protein was assumed to be associated with 5 µl of
cell volume (Mannery et al., 2010). R is the gas constant, T is temperature, n is
the number of electrons transferred, F is the faraday constant, and Eo = - 264
mV at a pH of 7.4. Data are presented as mean ± SD, n = 3.

Copyright © Wei Zhang 2015
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Chapter Five

The effect of DOX on expression of ECSOD/SOD3 in CM and CF

Introduction
Three forms of SOD exist in mammalian tissues: Cu,ZnSOD/SOD1,
MnSOD/SOD2 and ECSOD/SOD3. While Cu/Zn SOD is localized in cytosol, and
MnSOD in mitochondria, the ECSOD is the only SOD secreted into the
extracellular environment. It catalyzes the dismutation of •O2- to H2O2 and O2,
and maintains relatively low levels of •O2- in the extracellular environment. Due
to its special cellular localization, it has unique and irreplaceable roles in
maintaining the normal redox status in tissue.

SOD structure characteristics
The ECSOD/SOD3 gene has been mapped to human chromosome 4 and
mouse chromosome 5 and share 60% identity. In most species, ECSOD exists
as a 135 KDa homotetramer composed of two disulfide-linked dimers. As shown
in Figure 5.1, each subunit has a molecular weight of 24 KD and is composed of
(1) an amino-terminal signal peptide, which permits its secretion from the cell; (2)
an active domain binding copper and zinc with a strong homology with
Cu,ZnSOD; (3) a heparin-binding domain, which is a C-terminal domain
containing a group of six positively charged amino acids (4 arginine, 2 lysine).
This domain interacts with the negatively charged heparin sulfate proteoglycans
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on the cell surface or in the extracellular matrix (ECM).
ECSOD has a proteolytic cleavage site next to the heparin binding domain.
The proteolysis of the heparin binding domain can occur partially, to produce a
tetramer with low affinity for heparin (type B), or completely, so all of the 4
subunits lack the heparin-binding domain to produce tetramer with no affinity for
heparin (type A). If none of the subunits undergo proteolysis, the tetramer has a
strong affinity for heparin (type C). Type A and type B are found circulating in
plasma, while type C remains bound to the ECM, but can be released into
circulation by displacing it with heparin. The tissue bound forms constitute ~ 99%
of the total ECSOD (Fukai et al., 2002).

ECSOD tissue distribution and expression regulation
In contrast to the ubiquitous expression of Cu,ZnSOD and MnSOD, ECSOD
expression is restricted to several tissues. In mammalians, ECSOD expression
is highest in lung, kidney and aorta, while the heart and brain have lesser
amounts (Folz et al., 1997). On the cellular level, a higher level of ECSOD
expression was observed in alveolar type II cells, lung macrophages, vascular
smooth muscle cells, endothelial cells and some fibroblast cells.
The mechanism involved in ECSOD expression regulation is not wellunderstood. SP1/SP3 regulates ECSOD expression in human and mouse liver
cell lines and lung fibroblast cell lines (Zelko et al, 2004; 2008).

In human

vascular smooth muscle cells and lung alveolar type II cells, inflammatory
cytokines such as interferon (IFN)-γ and IL-4 upregulate the expression of
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ECSOD mRNA and protein while tumor necrosis factor (TNF)-α downregulates
the expression of ECSOD. Vasoactive factors such as histamine, vasopressin,
oxytocyn, endothelin-1, serotonin, and heparin markedly increase enzyme levels
in cultured arterial smooth muscle cells (Fukai et al., 1999).

Also, exercise

training and Angiotensin II upregulate ECSOD expression in smooth muscle cells
(Fukai at al., 1999, 2000).

In addition, ECSOD expression is uniformly

downregulated by a wide variety of oxidizing agents, such as xanthine oxidase,
paraquat, and t-butyl hydroperoxide in fibroblasts, although the mechanisms
involved are not clear (Stralin and Marklund, 1994).

ECSOD and cardiovascular disease
In the cardiovascular system, ECSOD is highly expressed in blood vessels,
particularly arterial walls. Also, ECSOD activity is 10-fold higher in the vessel
wall than in other tissues and constitutes up to 70 % of the total SOD activity in
aorta.

A body of evidence shows the protective role of ECSOD in the

cardiovascular system. ECSOD expression is reported to be reduced in patients
with coronary artery disease while overexpression of ECSOD in vascular
endothelial cells can protect against the oxidation of low-density lipoprotein (LDL),
a major contributing factor to the formation of atherosclerosis (Takatsu et al.,
2001; Laukkanen et al., 2001).

These data suggest that the low ECSOD

expression/activity contributes to the endothelial dysfunction in patients with this
disease. ECSOD also plays an important role in reducing myocardial infarct size
and preserving cardiac function.

For example, recombinant human ECSOD
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preserves cardiac function and reduces the level of tissue ROS following
ischemia/reperfusion in rat isolated hearts (Sioquist et al., 1991).

ECSOD-

transgenic mice show greater preservation of myocardial function after global
ischemia/reperfusion than their wild-type counterparts (Chen et al., 1996). In
addition, ECSOD can limit the interaction of •O2- with NO• to preserve the
bioavailability of NO. Cardiac-speciﬁc ECSOD overexpression attenuates ROS
levels and increases NO bioavailability in response to ischemia/reperfusion, thus
protecting against reperfusion injury (Obal et al., 2012).

This action also

prevents the excessive formation of the highly reactive and toxic peroxynitrite.

Our questions and research goal
Kliment et al (2009) reported that lack of ECSOD leads to increases in
myocardial apoptosis and significantly more left ventricle fibrosis in mice treated
with DOX. This means that ECSOD likely plays an important role in normal heart
defense against DOX induced cardiotoxicity. Thus, investigating the regulation of
SOD3 expression in heart, especially when heart is exposed to DOX, may help
us better understand how DOX causes heart damage.

However, there are no

reports regarding how DOX affects SOD3 expression in heart, especially in
different cell types of heart tissue. Here, neonatal cardiomyocytes and cardiac
fibroblastsfrom WT mice were treated with a range of DOX concentrations, and
SOD3 mRNA and protein expression measured. This study characterized the
effects of DOX on SOD3 expression in these two cell types.
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Materials and Methods
Cell culture and treatment
Primary CM and CF were obtained from WT C57BL neonatal mice at 1–3 days
of age and cultured as described in Chapter 3. Cells were treated with varying
concentrations of DOX for the indicated times and cells harvested for detection of
SOD3 expression.

RNA extraction and real-time quantitative PCR (qRT-PCR)
Total RNA extraction, cDNA preparation and RT-PCR were conducted as
described in Chapter 2.

Primers and UPL probes used to detect SOD3 are

shown in Table 4.1.

Immunoblot Assay
Immunoblot assays were conducted as described in Chapter 4. Rabbit antiECSOD pAb was a generous gift from Dr. Ladislav Dory, University of North
Texas.

Statistical analysis
All data are expressed as the mean ± SD for n = 3 per group, as detailed in the
Figure Legends. In studies comparing multiple groups to the same control group,
statistical analysis was performed with one-way ANOVA followed by Dunnett's
post-test.
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Results
DOX decreased expression of SOD3 in CM
CM were treated with different concentrations of DOX for 24 h.

DOX

concentrations were chosen based on the results of the MTT assay to avoid the
high DOX concentrations that cause excessive cell death.

DOX decreased

ECSOD mRNA (Figure 5.2A) and protein (Figure 5.2B) expression in a dosedependent manner.

In contrast, DOX significantly increased MnSOD protein

expression levels, while it had no significant effects on Cu,ZnSOD expression
(Figure 5.2B). DOX-induced cell apoptosis was demonstrated by PARP cleavage.
CM further treated with 0.5 µM DOX for various time periods showed that the
down-regulation of ECSOD mRNA and protein level occurred at 8 h, 16 h and 24
h after DOX treatment (Figure 5.3).

DOX affectss on the expression of SOD3 in CF
CF were treated with various concentrations of DOX for 24 h, and showed that
the lowest concentration of DOX (0.5 µM) decreased ECSOD mRNA and protein
expression.

However, the high concentration of DOX (3 µM) significantly

increased the expression of ECSOD protein, with no significant change in
ECSOD mRNA expression. Dox treatment also increased MnSOD expression at
high concentrations (1 and 3 µM) of DOX (Figure 5.4).

DOX-induced cell

apoptosis was demonstrated by PARP cleavage.
CF were further treated with 3 µM DOX for various time periods, and showed
that the increase of ECSOD protein expression began about 16 h after DOX
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treatment. However, there was no obvious change in the mRNA expression
(Figure 5.5).

Discussion
A number of studies suggest that the administration of a wide variety of
enzymatic and nonenzymatic antioxidants can protect against oxidant-induced
tissue injury, both in animal models and in human. Since ECSOD expression
and/or activity are decreased in multiple diseases, it is interesting to entertain the
idea of ECSOD as a potential target for therapy to improve antioxidant capacity
and restore the redox balance.

Thus, a further understanding of the role of

ECSOD in the pathogenesis of oxidant-mediated diseases as well as the
regulatory mechanism of ECSOD expression will provide insight into the potential
therapeutic possibilities of this protein.
Our study is the first to show the effects of DOX treatment on ECSOD
expression in CM and CF. It is important to note that the ECSOD expression in
CM and CF showed different responses to DOX treatment. This means that
there must be different machinery that controls ECSOD expression in these two
cell types. We expect the decrease of ECSOD expression in CM to exacerbate
the DOX-induced oxidative stress, while the increase of ECSOD in CF could
present the cellular response to this stress. How these two sources of ECSOD
coordinate with each other and how these ECSOD from different sources
contribute to DOX-induced pathological changes in heart will be an important
avenue to investigate.
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In addition, compared to CMs, CFs have much higher ECSOD expression at
both mRNA and protein levels (Figure 5.6). The different basal levels of ECSOD
expression and different expression regulation mechanisms in CM and CF
indicate that ECSOD expression in whole heart tissue needs to be evaluated
carefully because measuring total ECSOD expression in heart is not able to
distinguish changes of ECSOD expression in these two different cell populations.
Another interesting finding is the inconsistent changes of ECSOD mRNA
expression and protein expression in CF treated with 3 µM DOX. The disparity
between ECSOD mRNA and protein expression are also reported in other cells
(Folz et al., 1994). These data indicate a role of post-transcriptional regulation in
maintaining optimal enzyme levels in various tissues and in response to various
stressors.
Based on these data, many further studies will be important, such as
investigating post-transcriptional modulation of ECSOD, rates of protein
synthesis and secretion, and the extent of protein degradation following DOX
treatment.

These studies will help us better understand the expression

regulation of ECSOD, and how this contributes to DOX induced cardiotoxicity.
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Figure 5.1. Schematic diagram of ECSOD functional domains in protein.
The ECSOD protein can be divided into four functional domains: (1) the signal
sequence, cleaved during synthesis; (2) the glycosylated N-terminus; (3) the
catalytic region, which bears the highest level of homology to Cu,Zn SOD; (4) the
positively charged heparin-binding domain.
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A

B

Figure 5.2. DOX treatment increased MnSOD but decreases ECSOD
expression in CM culture in a dose-dependent manner. CMs were treated
with varying concentrations of DOX for 24 hr, then mRNA expression of SOD3
was measure by real-time PCR (A) and protein expression of Cu,ZnSOD,
MnSOD and ECSOD was detected by Western blot (B).

DOX-induced cell

apoptosis was demonstrated by PARP cleavage. Each bar represents the mean
+ SD. (n=3, *, p < 0.05 by Dunnett's post-test after one-way ANOVA).
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A

B

Figure 5.3. DOX treatment decreased ECSOD expression in CM culture.
CMs were treated with 0.5 µM DOX for varying time periods, and mRNA
expression of ECSOD was measured by real-time PCR (A). Protein expression
of ECSOD was detected by Western blot (B). DOX-induced cell apoptosis was
demonstrated by PARP cleavage. Each bar represents the mean + SD. (n=3, *, p
< 0.05 by Dunnett's post-test after one-way ANOVA).
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A

B

Figure 5.4. DOX treatment changes expression of superoxide dismutases in
CF culture in a dose-dependent manner.

CFs were treated with varying

concentrations of DOX for 24 hr, and mRNA expression of ECSOD was
measured by real-time PCR (A) and protein expression of Cu,ZnSOD, MnSOD
and ECSOD was detected by Western blot (B). DOX-induced cell apoptosis was
demonstrated by PARP cleavage. Each bar represents the mean + SD. (n=3, *, p
< 0.05 by Dunnett's post-test after one-way ANOVA).
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A

B

Figure 5.5. DOX (3 µM) treatment increased ECSOD expression in CF
culture. CFs were treated with 3 µM DOX for varying time periods, and mRNA
expression of ECSOD was measured by real-time PCR (A). Protein expression
of ECSOD was detected by Western blot (B). DOX-induced cell apoptosis was
demonstrated by PARP cleavage. Each bar represents the mean + SD. (n=3, *,
p < 0.05 by Dunnett's post-test after one-way ANOVA).
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B

A
*

Figure 5.6. CF has higher ECSOD expression compared to CM.

mRNA

expression of ECSOD was measure by real-time PCR (A) while protein
expression of ECSOD was detected by Western blot (B). Each bar represents
the mean + SD. (n=3, *, p < 0.05 by Student t test).
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Chapter Six

Conclusion, general discussion and future studies

Conclusion and general discussion
The ATP-dependent efflux transporter MRP1 has been a major subject of
scientific and clinical interest ever since its first characterization in 1992 (Cole et
al., 1992). Due to its role in multidrug resistance development in cancer cells,
MRP1 is considered as a diagnostic marker and a therapeutic target to increase
the efficacy of a variety of chemotherapy drugs, including anthracyclines
(Schaich et al., 2005; Faggad et al., 2009; He et al., 2011). In those situations,
inhibiting MRP1 through pharmacological inhibitors is a potential approach to
overcome the anti-cancer drug resistance. However, based on its ability to efflux
a wide range of endo-/xenobiotics, MRP1 has important physiological functions in
normal tissues in unstressed or stressed conditions. Thus, generally inhibiting
MRP1 through pharmacological inhibitors may impair the normal tissues’ defense
ability. So far, the functions of MRP1 in normal tissue defense have not been
investigated in depth compared to its effects on drug therapy efficacy in cancer.
The work presented in this dissertation investigated the role of MRP1 in the
defense of the normal mouse heart. Specific emphasis was put on its potential
protective function in chemotherapy drug DOX-induced cardiotoxicity, since
DOX-induced cardiotoxicity is a severe dose-limiting side effect in cancer
patients receiving this effective anti-cancer medicine.
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DOX-induced heart failure is now widely recognized as a high risk
complication of cancer chemotherapy experienced by a growing number of
cancer survivors. However, there are very few approaches with limited positive
effects to prevent or alleviate this life-threatening toxicity. DOX causes oxidative
stress in cardiac tissue by promoting the generation of ROS, which further
induces the damage to macromolecules, including protein, DNA and lipid. Thus,
identifying and studying the genes that may be involved in the oxidative stress
regulation will be useful to find the potential strategies to reduce or even prevent
DOX-induced cardiotoxicity.
The clinical data showing the correlation between SNPs of MRP1 and patients’
susceptibility to DOX-induced cardiotoxicity are informative (Cole., 2014b).
These data imply that MRP1 is involved in the heart’s defense against DOX
toxicity. Further functional studies in our laboratory show that HEK cells that
overexpress an MRP1 SNP (Gly671Val) are more sensitive to DOX toxicity
compared to cells expressing WT MRP1. This MRP1 SNP actually impairs more
than 85% of MRP1’s ability to efflux GS-HNE, resulting in a significantly higher
intracellular accumulation of GS-HNE (Jungsuwadee et al., 2012). These data
suggest that MRP1 modulates the cells’ sensitivity to DOX, and this is
accomplished not simply by effluxing DOX, but by effluxing other important
substrates, such as GS-HNE. To test this hypothesis in heart tissue, WT and
Mrp1-/- mice were used as a model. The unique advantage of this model is that
unlike human MRP1, murine Mrp1 is not able to efflux DOX, but murine Mrp1
retains the ability to efflux other substrates of human MRP1, such as GSH,
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GSSG and GS-HNE. Therefore, the Mrp1-/- mouse provides a good model to
examine the role of Mrp1 in DOX-induced cardiotoxicity separately from Mrp1
effects on DOX retention.

The role of Mrp1 in normal heart defense against DOX toxicity
The data presented in this dissertation provide insights into the role of Mrp1 in
heart defense against DOX toxicity using both in vivo and in vitro model systems.
In Chapter 2 of this dissertation, WT and Mrp1-/- mice were treated chronically
with DOX, followed by measurement of cardiac function and heart damage.
Mrp1-/- mice showed more severe body weight loss and delayed recovery from
hemotoxicity. These data imply that Mrp1 could play important protective roles in
organs other than the heart. These findings are consistent with the published
data demonstrating that Mpr1 protects normal tissues like skin and brain against
xenobiotics. Further echocardiogram studies showed that there is no difference
in left ventricular function between saline treated WT and Mrp1-/- mice. However,
following chronic DOX treatment, Mrp1-/- mice had significantly more severe left
ventricle dysfunction compared to WT mice, presenting as significantly lower
fractional shortening and ejection fraction. This functional change was consistent
with the higher BNP expression level found in DOX treated Mrp1-/- mouse heart.
These observations suggest that under normal physiological conditions, loss of
Mrp1 does not affect cardiac function; however, under stressful conditions, such
as treatment with DOX, and when the stress exceeds a certain threshold, the
heart of Mrp1-/- mice showed an impaired defensive ability to respond to the
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stress, consequently resulting in functional damage. These data well support our
initial hypothesis regarding the protective role of Mrp1 in heart.
The extent of apoptosis was also measured in heart sections from mice
chronically-treated with DOX. The quantitative data showed that following DOX
treatment, Mrp1-/- mouse heart had significantly more apoptotic cells than WT
mice. We believe this higher apoptosis contributes to the more severe cardiac
functional damage in Mrp1-/- mice. This is consistent with our previous electron
microscopy studies, which show that compared to WT mice, Mrp1-/- mice have
more nuclear injury, including early apoptotic changes in nuclei in heart after a
single intravenous administration of DOX. The effects of Mrp1 on DOX-induced
apoptosis were also observed in our in vitro study, which used isolated neonatal
mice cardiomyocytes and cardiac fibroblasts from WT and Mrp1-/- pups. In CM
and CF cultures, the same concentration of DOX showed that compared to WT
cells, Mrp1-/- cells are more sensitive to DOX toxicity, indicated by lower cell
survival, more PARP cleavage, more caspase3 cleavage and more γH2A.X
expression. Those data indicate that Mrp1 similarly protects CM and CF against
DOX cytotoxicity. Taken together, these data demonstrate the cardiac protective
role of MRP1 in both in vivo and in vitro model systems.

The role of Mrp1 in GSH/GSSG homeostasis
The work presented in this dissertation further examined the mechanisms by
which Mrp1 protects in the heart following DOX treatment, especially in GSH
homeostasis, GS-HNE accumulation and protein oxidative damage.
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In Chapter 4 of this dissertation, loss of Mrp1 increased basal intracellular
levels of GSH and GSSG in treatment-naïve and saline-treated heart tissue, CM
culture and CF culture.

However, no differences were observed in the

expression of GSH enzymes between genotypes in the absence of DOX
treatment. These data are consistent with the reported function of Mrp1 to efflux
GSH and GSSG.
DOX treatment further increased intracellular levels of GSH and GSSG in
Mrp1-/- CM and CF. This is likely due to the increased GSH synthesis since the
expression of GSH synthetic enzymes, GCLc, GCLm and GSS, was increased in
DOX-treated Mrp1-/- cells only. Since all the three enzymes are regulated by
Nrf2, we examined whether the Nrf2 pathway was activated in DOX treated
Mrp1-/- cells. We found that the expression of Nqo1 and HO-1, two additional
downstream genes in the Nrf2 pathway, were also significantly higher in DOX
treated Mrp1-/- cells compared to WT cells. We concluded that in response to
DOX treatment, the Nrf2 pathway was activated in Mrp1-/- cells, and increased
the transcription of its downstream genes, including the GSH synthesis enzymes
and finally contributed to the elevated intracellular level of GSH and GSSG.
However, the elevated GSH was not able to protect Mrp1-/- cells against DOXinduced oxidative stress. Finally, although the elevated GSH level was not able
to protect Mrp1-/- mouse heart or Mrp1-/- cells against DOX toxicity, we found a
significantly lower GS-HNE level in treatment-naïve mouse heart (Deng et al.,
submitted). These data mean that the higher GSH level in Mrp1-/- mouse heart
does protect against ‘background’ levels of oxidative stress.
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An important observation is that Mrp1 deficiency increases the GSH level in
the heart and in CM/CF. This means that MRP1-mediated efflux of GSH plays
an important role in maintaining the normal intracellular GSH level. Usually, GCL
is recognized as the major determinant of cellular GSH homeostasis. It catalyzes
the first and rate-limiting step in de novo synthesis of GSH. The expression and
activity of GCL is tightly controlled by a complex regulation at several levels,
including: transcriptional activation by oxidative stress; reversible formation of the
disulfide bond between its two subunits (GCLc and GCLm); and feedback
inhibition by GSH. In out study, without a significant difference in GCLc and
GCLm expression, the treatment-naïve and saline-treated Mrp1-/- mice heart and
Mrp1-/- CM/CF have a higher GSH level compared to WT mice heart and cells.
These data indicate the importance of Mrp1-mediated efflux in intracellular GSH
level regulation, regardless of the GCL expression and activity changes.

In

addition, compared to WT cells, the DOX treated Mrp1-/- cells have significantly
higher expression of GCLc and GCLm, which caused a further increase in the
GSH pool, although there is already a higher basal level of GSH in Mrp1-/- cells.
All of these data indicate that GCL is not the only sensor and factor that is
responsible for the intracellular GSH level, and that Mrp1-mediated efflux is
another important determinant.

The role of Mrp1 in HNE detoxification
Another important consequence of DOX-induced oxidative stress is lipid
peroxidation. HNE is one of the major toxic products of lipid peroxidation and
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conjugation with GSH is its major metabolism pathway.

GS-HNE was

investigated in this study because our previous work demonstrated that Mrp1 is
the sole, or at least the most important, transporter in mouse heart to efflux GSHNE. We expected that loss of Mrp1 would cause GS-HNE accumulation in
mouse heart, especially under the oxidative stress induced by DOX. In Chapter
4, DOX treatment significantly increased the GS-HNE detected in mice heart
tissue.

These data were consistent with the expectation that DOX cause

oxidative stress in cardiac tissue, leading to lipid peroxidation. However, unlike
our expectation, there was no difference in GS-HNE levels between WT and
Mrp1-/- mouse heart. We believe this could be due to the complex compensating
effects in Mrp1-/- mouse heart.

Thus, Mrp1 deficiency may saturate other

detoxification pathways of HNE. To answer this question, we would need to
quantitate other metabolites of HNE, such as DHN, HNA, GS-DHN and GS-HNA.
More information regarding the biological activities of these HNE metabolites and
whether they are substrates of Mrp1 will also be helpful in evaluating the effects
of Mrp1 on HNE detoxification.

The role of MRP1 in cellular compartments
In Chapter 2 and 3, our studies show that the loss of Mrp1 causes more
nuclear injury in mouse heart following acute DOX treatment, more apoptosis in
hearts of mice treated chronically with DOX, and more cell apoptosis and DNA
damage in CM/CF culture.

Thus, it appears that the most severe damage

caused by Mrp1 deficiency mainly occurs in the nucleus. This raises a question
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regarding the potential function of Mrp1 in nucleus. A previous study in our
laboratory has shown that Mrp1 is localized in sarcolemmal membrane of
cardiomyocytes in heart in untreated mice. However, upon treatment with DOX,
the expression of Mrp1 is significantly increased in the heart mitochondrial
fraction. However, we did not examine the nuclear localization of Mrp1 in heart
tissue. Although a nuclear localization sequence was not found in MRP1, two
publications from the same research group reported that the nuclear MRP1
contributes to multidrug resistance in human mucoepidermoid carcinoma cell
lines (Cai et al., 2011; Cai et al., 2013). In addition, Rajagopal et al (2003)
reported that human MRP1 is present in a perinuclear region positive for
lysosomal markers, and may rescue cancer cells by sequestering the toxic
substance away from the nucleus.

However, further studies are needed to

determine whether this occurs in heart.
In addition, loss of Mrp1 impairs GSH efflux and could cause lower GSH
levels in the extracellular environment and finally accelerate oxidative damage in
the extracellular environment. Extracellular GSH can also be broken down in the
extracellular space by γGT and dipeptidase, thus producing cysteine. The lower
extracellular GSH concentration could affect the cysteine/cystine balance, which
is also critical for maintaining extracellular redox status. In Chapter 4, our in vitro
studies found that exogenous cell impermeable GSH (10 mM) eliminated the
difference in cell viability between DOX treated-WT and Mrp1-/- cells. Also, the
expression of ECSOD, the only SOD existing in the extracellular environment, is
reduced in saline and DOX-treated Mrp1-/- CM. The lower ECSOD expression
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may contribute to the Mrp1-/- CM’s sensitivity to DOX.

These data imply

potential effects of Mrp1 on redox status in the extracellular environment, and
indicate the need for further studies.
Clinical significance of this study
During the past two decades, the focus of MRP1 research has been on the
negative effects of MRP1 expression, especially its contributions to multidrug
resistance in cancer cells. Therefore, the use of MRP1 inhibitors in the treatment
of cancer has been the main therapeutic goal (Burkhart et al., 2009; Sirisha et al.,
2011; Zhang et al., 2014; Ma et al., 2014). Although this may be beneficial to
sensitize multidrug resistant cancer cells to anticancer drugs, our research shows
that inhibiting MRP1 in the heart may potentiate the chemotherapy drug-induced
cardiotoxicity. These studies provide critical information regarding the potential
adverse sequelae of introduction of MRP1 inhibitors as adjuncts to clinical
chemotherapy of multidrug resistant tumors. In addition, genetic variants of the
MRP1 gene have been found in clinical patients and multiple SNPs are found to
be associated with cancer patients’ susceptibility to DOX-induced cardiotoxicity.
Our study may provide some explanations for these clinical observations if the
SNPs impair MRP1’s expression or activity.

It will potentially further help to

identify these susceptible patients and modify chemotherapy strategies for these
individuals and thus prevent such drug-induced toxicity.

Future studies
Based on the results in this dissertation, the following experiments warrant
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future investigation:

What are the consequences of increased GSSG in Mrp1-/- mouse heart?
In addition to the higher GSH level, we also demonstrated a significantly
higher GSSG level in DOX-treated Mrp1-/- mouse heart and Mrp1-/- CM/CF.
Reversible protein S-glutathionylation as a common feature of redox signal
transduction is able to regulate the activities of several redox sensitive proteins.
Increased intracellular GSSG concentration following microinjection or inhibition
of the efflux through Mrp1 has been shown to cause glutathionylation of cysteinecontaining proteins, and consequently change their cellular function, finally
causing cell death (Park et al., 2009). Investigating the effects of elevated GSH
and GSSG levels in Mrp1-/- mouse heart and cells on glutathionylation
modification of proteins could provide new insights regarding how Mrp1
modulates the sensitivity to DOX induced cardiotoxicity.

What are the concentrations of HNE and HNE metabolites?
As we discussed above, in addition to conjugation with GSH, HNE has other
detoxification pathways.

Measurement of the concentration of other HNE

metabolites, such as HNA, DHN, GS-HNA, GS-DHN and HNE itself will help to
better understand how loss of Mrp1 affects the detoxification of HNE and the
consequence of lipid peroxidation.

Does Mrp1 protect heart through other functions in addition to its transport
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activity?
Another

ABC

transporter,

P-glycoprotein

(Pgp)

/MDR1,

has

been

demonstrated to have anti-apoptotic activity independent of its transporter activity
(Tainton et al., 2004). In that study, lymphoma cells expressing ATPase-mutant
Pgp cannot efflux chemotherapeutic drugs but remained relatively resistant to
apoptosis induced by vincristine.

In addition, the anti-apoptotic effect of this

mutant Pgp is not affected by antibodies that inhibit the efflux function of the
protein. Those data are consistent with a dual activity model for Pgp-induced
MDR involving both ATPase-dependent drug efflux and ATPase-independent
inhibition of apoptosis.

It would be important to investigate whether other

functions of Mrp1 beyond its transport activity could contribute to the protective
role of Mrp1 in DOX toxicity. Use of an Mrp1-specific inhibitor or development of
cells expressing Mrp1 with mutations that delete its ability to transport will help to
answer this question. Further investigation of Mrp1’s localization especially in
mitochondria or nucleus and Mrp1’s interaction with anti-apoptotic proteins may
provide more insight.

Use human induced pluripotent stem (iPS) cells derived CM to study the
role of human MRP1 against DOX toxicity.
Since murine Mrp1 does not efflux DOX, here we took advantage of the
mouse model to investigate the potential function of Mrp1 in oxidative stress
regulation. However, this difference between human MRP1 and mouse Mrp1
may limit the clinical significance of this study. Human induced pluripotent stem
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(iPS) cell-derived cardiomyocytes provide a good model to aid drug discovery
and improve the predictability of drug efficacy and toxicity screens. Investigation
of the function of human MRP1 in these cells would/could provide valuable
insight regarding the importance of MRP1 in DOX-induced cardiotoxicity in
patients.

What are the concentrations of GSH and GSSG in specific intracellular
organelles?
In recent years, increasing evidence demonstrates the existence of welldefined compartments of redox systems within cells, each exhibiting a unique
redox environment (Circu et al., 2008). Intracellular GSH is compartmentalized
within the mitochondria, nucleus and endoplasmic reticulum (ER), all of which
constitute separate redox pools that are distinct from the cytoplasmic pool in
terms of distribution of the GSH and GSSG forms, their redox potential and their
control of cellular activities. Mrp1 is localized in plasma membrane and in the
membrane of intracellular organisms, including lysosome, trans-Golgi vesicles
and mitochondria, as shown in studies using techniques such as Western blot,
immunofluorescence, and immunogold electron microscopy (Rajagopal et al.,
2003; Gennuso et al., 2004; Jungsuwadee et al., 2009). Thus, it will be very
important to determine whether such localized expression of Mrp1 affects
GSH/GSSG homeostasis in these distinct cell compartments. However, precise
quantification of the GSH and GSSG in specific intracellular compartment is
difficult.
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In summary, this study is the first to document a protective role of Mrp1 in
DOX-induced cardiotoxicity despite equal DOX concentrations. It gives critical
information regarding the potential adverse sequelae of introduction of MRP1
inhibitors as adjuncts to clinical chemotherapy of multidrug resistant tumors. It
will also potentially help to identify the susceptible patients and modify
chemotherapy strategies for these individuals and thus prevent such druginduced toxicity. Further studies as we discussed above will provide essential
information to elucidate the mechanism of Mrp1-mediated cardiac protection.

Copyright © Wei Zhang 2015
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Appendices
Appendix A
List of abbreviations
ABC
ADP
ARE
ATP
BNP
CM

ATP-binding cassette
Adenosine diphosphate
Antioxidant response element
Adenosine triphosphate
B-type natriuretic peptide
Cardiomyocytes

CF

CDHNardiac fibroblasts
Cu,Zn-superoxide dismutase
1,4-dihydroxy-2-nonene
Doxorubicin
Extracellular superoxide dismutase
Ejection fraction
Redox potential
Fractional shortening
Glyceraldehyde-3-phosphate dehydrogenase
Glutamate-cysteine ligase catalytic subunit

Cu,ZnSOD/SOD1
DHN
DOX
ECSOD/SOD3
EF
Eh
FS
GAPDH
GCLc
GCLm
Gpx
GR
Grx
GST
GSS
GSH
GSSG
GS-HNE
γGT
HO-1
HNA
HNE
HPLC
HRP

Glutamate-cysteine ligase regulatory subunit
Glutathione peroxidase
Glutahione reductase
Glutaredoxin
Glutathione S-transferase
Glutathione synthetase
Glutathione
Glutathione disulfide
Glutathione conjugates of 4-Hydroyx-2-nonenal
γ glutathione transpeptidase
Heme oxygenase 1
4-hydroxy-2-nonenoic acid
4-Hydroyx-2-nonenal
High performance liquid chromatography
Horseradish peroxidase
Hydroxy
2
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iPS cells

induced pluripotent stem cells

LVEF
LVFS
LVIDd
LVIDs
LVPWd
LVPWs
LTC4
LY
MDA

Left ventricular ejection fraction
Left ventricular fractional shortening
Left ventricular end-diastolic dimension
Left ventricular end-systolic dimension
Left ventricular diastolic posterior wall thickness
Left ventricular systolic posterior wall thickness
Leukotriene C4
Lymphocyte
Malondialdehyde

MnSOD/SOD2
MBB
Mrp1/Abcc1

Mn superoxide dismutase
Monobromobimane
Multidrug resistance-associated protein 1
Mrp1 knock out
Multiple reaction monitoring
Membrane spanning domain

Mrp1-/MRM
MSD
NBD
NQO1
Nrf2
Pgp
Prx
RNS
ROS
SNPs
TMD
Trx
WBC
WT

Nucleotide binding domain
NAD(P)H dehydrogenase, quinone 1
Nuclear factor-like 2
P-glycoprotein
Peroxiredoxin
Reactive nitrogen species
Reactive oxygen species
Single nucleotide polymorphisms
Transmembrane domain
Thioredoxin
White blood cell
Wild type
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Appendix B
Isolation of neonatal mice cardiomyocytes and cardiac fibroblasts
Solutions:
Hanks balanced salt solution without Ca2+ and Mg2+ (14185-052, Life
Technologies, CA)
Enzyme solution: 10mg collagenase in 30 m l HBSS (collagenase type 2:
Worthington Biochemical Corp., Lakewood, NJ)
DMEM (10965, Life Technologies, CA)
Fetal bovine serum (FBS) (10438-026, Life Technologies, CA)
Penicillin/streptomycin (15140-122GIBCO, Grand Island, NY)
Protocol:
1. 1–3 days old pups are sacrificed by cervical dislocation. The hearts are
removed and placed in cold HBSS without Ca2+ and Mg2+.
2. The hearts are washed with HBSS for several times to remove most of the
red blood cells and the atria are removed and discarded.
3. The ventricles are transferred to 1 mL of enzyme solution and minced into
small pieces.
4. Tissue is placed into a 10 mL beaker and a small stir bar is added.
5. 4 mL of enzyme solution is added for a total of 5 mL. The beaker is placed
in a dish of warm water bath (37°C) on a stir plate and the tissues agitated
for 10 min.
6. At the end of each cycle of agitation, the tissue pieces are allowed to settle.
Then, the supernatant is removed and added to a 15 mL centrifuged tube
with 0.5 mL FBS with a final FBS concentration of 10% and centrifuged for
10 min at 800 rpm. (Note: the supernatant from the first digestion may
contain mainly red blood cells and should be discarded)
7. At the end of centrifugation, the supernatant is discarded and the cell pellet
is resuspended in 2 mL DMEM and placed in a 6-well culture dish.
8. Step 5 -7 are repeated until all tissue has been digested. This can take up
to 10 individual digests for the ventricular tissue.
9. After pre-plating period (about 2 hours) to allow the non-myocytes
predominantly fibroblasts to adhere to the plastics, the suspensions mainly
including cardiomyocytes are collected form cell culture dish by gently
washing with culture medium and collected in a 15 mL centrifuge tube and
centrifuged at 800 rpm for 10 min. The cell pellet mainly including
cardiomyocytes are resuspended in DMEM medium and plated in cell
culture dish with appropriate cell density (about 105/cm2). The nonmyocytes predominantly fibroblasts which adhere to the plastics before are
maintained in DMEM medium with 10% FBS.
10. CM numbers are determined by counting living cells (with Trypan blue)
using a hemocytometer.
11. For CM culture, 100 μmol/L Bromodeoxyuridine (Sigma Chemical Co) is
added during the first 48 h of culture to prevent proliferation of
160

nonmyocytes.
12. CF cultures are used for experiments after two passages to eliminate other
nonmyocytes.
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